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Prostate cancer is the most common cancer in Western countries. As the disease 
proceeds to castration resistant phase, it often leads to death due to lack of effective 
treatment methods and lack of knowledge of molecular mechanisms leading to it. 
Migration and invasion inhibitory protein (MIIP) has been shown to have tumor 
suppressing effects in other cancers. The effect of it in prostate cancer has not been 
previously studied. The aims of this study were to discover the effect of MIIP on growth 
and migration of prostate cancer cells and to detect possible mutations and a single 
nucleotide polymorphism (SNP) rs2295283 previously shown to affect breast cancer 
risk from the gene.  
DU145 and LAPC-4 prostate cancer cell lines were used. DU145 cells were stably 
transfected with a plasmid containing MIIP and an empty control plasmid. LAPC-4 
cells were transfected with small interfering RNAs (siRNAs) targeting MIIP and a 
control siRNA. Proliferation of the cells was studied with image analysis and 
alamarBlue methods. Migration was studied with scratch assay. Mutations and SNPs 
were studied by sequencing. 
Clear results from the effects of silencing MIIP in LAPC-4 cells were not achieved. 
In the proliferation assays, image analysis and alamarBlue methods gave contradictory 
result and due to difficulties in image analysis, results from alamarBlue should be 
considered more reliable. AlamarBlue assay showed the metabolic activity of DU145 
cells overexpressing MIIP to be significantly lower than in cells transfected with control 
vector. However, DU145 cells overexpressing MIIP migrated significantly faster that 
cells transfected with control vector. Mutations in the gene were not detected and SNP 
rs2295283 was not found to be associated with prostate cancer risk. 
It seems unlikely that MIIP would have a significant effect in most prostate cancer 
cases. However, it is possible that the role of MIIP is more notable in some of prostate 
cancer subtypes. More experiments are needed to fully uncover the effect of MIIP in 
prostate cancer cells. 
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Eturauhassyöpä on miesten yleisin syöpä länsimaissa. Taudin edetessä hormoneista 
riippumattomaan vaiheeseen se johtaa usein kuolemaan, sillä tarpeeksi tehokkaita 
hoitokeinoja ei ole. Eturauhassyövän syntyyn ja etenemiseen liittyvät molekyylitason 
mekanismit ovat huonosti tunnettuja, mikä rajoittaa uusien hoitokeinojen kehittämistä. 
Migraatio- ja invaasioinhibiittoriproteiinilla (MIIP) on havaittu syöpää ehkäiseviä 
vaikutuksia muissa syövissä. Sen vaikutusta eturauhassyövässä ei ole aiemmin tutkittu. 
Tutkimuksen tavoitteena oli selvittää MIIP:n vaikutusta eturauhassyöpäsolujen kasvuun 
ja migraatioon sekä tunnistaa mahdollisia mutaatioita tai kohonneeseen 
rintasyöpäriskiin liitettyä yhden nukleotidin polymorfismia (SNP) rs2295283 geenissä. 
Tutkimuksissa käytettiin DU145- ja LAPC-4-eturauhassyöpäsolulinjoja. DU145-
solut transfektoitiin pysyvästi MIIP:n sisältävällä plasmidilla sekä kontrolliplasmidilla. 
LAPC-4-solut transfektoitiin MIIP:in kohdistuvilla pienillä häiritsevillä RNA:illa 
(siRNA) ja kontrolli-siRNA:lla. Solukantojen kasvua tutkittiin kuva-analyysin ja 
alamarBlue-menetelmän avulla. Migraatiota tutkittiin naarmukokeella. Mutaatioita ja 
SNP:a tutkittiin sekvensoimalla. 
MIIP-geenin hiljentämisen vaikutuksista LAPC-4-soluissa ei saatu selkeitä tuloksia. 
Solukantojen kasvua arvioivissa kokeissa kuva-analyysin ja alamarBlue-menetelmän 
avulla saatiin ristiriitaisia tuloksia. Kuva-analyysiin liittyvien ongelmien takia, 
alamarBlue-menetelmän tuloksia tulee pitää luotettavampina. AlamarBlue-kokeissa 
huomattiin, että MIIP-geeniä yli-ilmentävien DU145-solukantojen metabolinen 
aktiivisuus oli huomattavasti matalampi kuin kontrollien. MIIP-geeniä yli-ilmentävien 
DU145-solukantojen migraatio oli kuitenkin odotusten vastaisesti huomattavasti 
nopeampaa kuin kontrollien.  Mutaatioita geenissä ei havaittu eikä SNP rs2295283:n 
huomattu liittyvän kohonneeseen eturauhassyöpäriskiin.  
Vaikuttaa epätodennäköiseltä, että MIIP:lla olisi yleisesti merkittävää vaikutusta 
eturauhassyövän synnyssä tai etenemisessä. On kuitenkin mahdollista, että MIIP:n rooli 
yksittäisissä eturauhassyövän alatyypeissä voi olla suurempi ja jatkotutkimuksia 
tarvitaan tämän selvittämiseksi. 
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1. INTRODUCTION 
Prostate cancer (PC) is the most frequently diagnosed cancer in men and the second 
most common cause of cancer related deaths in Western countries (American Cancer 
Society 2011; European Cancer Observatory 2011). Most PCs grow quite slowly and 
remain confined to the prostate (Abate-Shen and Shen 2000). Organ-confined PCs are 
often relatively successfully treated with prostatectomy or radiation to remove or 
destroy the cancerous tissue (Heidenreich et al. 2012). Nevertheless, if the cancer is not 
detected early enough, or in more aggressive forms of PC, it can advance to invasive 
and metastatic stages, which usually lead to death (Abate-Shen and Shen 2000). 
Treatment of these more advanced stages of PC is more difficult. Because most PCs are 
androgen-dependent in the beginning, the standard treatment for advanced disease is 
androgen deprivation (Tammela 2012). However, as PC progresses during hormonal 
treatment, it turns from androgen-dependent to castration-resistant PC (CRPC) and 
androgen deprivation stops working (Best et al. 2005). Newer treatment methods have 
been developed, but they often offer only few more months in the life expectancy 
(Higano et al. 2009; Mita et al 2009; Tran et al. 2009; de Bono et al. 2010; Kantoff et al 
2010; de Bono et al. 2011). PC is a very heterogeneous and complex disease and 
molecular mechanisms behind initiation and progression of it remain largely unclear 
(Barbieri and Tomlings 2014). Thus, better biological understanding is needed in order 
to be able to develop more efficient treatment methods.  
Migration and invasion inhibitory protein (MIIP) has been seen to function as a 
possible tumor suppressor in gliomas. MIIP binds and inhibits insulin-like growth factor 
binding protein-2 (IGFBP-2) (Song et al. 2003), which is overexpressed in several 
cancers including prostate cancer (Kanety et al. 1993). The MIIP gene is also located on 
a chromosome region known to be deleted in various cancers including prostate cancer 
(Wang et al. 2011). The effect of it in prostate cancer has not been previously studied. 
The aim of this thesis was to study the influence of MIIP on growth and migration 
of prostate cancer cells by overexpressing and silencing the gene in prostate cancer 
cells. Possible mutations and certain previously found single nucleotide polymorphisms 
(SNPs) were also studied by sequencing. 
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2. NORMAL ANATOMY AND FUNCTION OF THE 
PROSTATE GLAND  
The prostate is a sex gland of the male reproductive system. It is approximately walnut 
sized and shaped and is located below the bladder, where it surrounds a part of the 
urethra. Location of the prostate gland in the male reproductive system can be seen in 
Figure 1. The prostate parenchyma can be divided into four distinct zones; peripheral 
zone, central zone, transitional zone and periurethral zone. The peripheral zone contains 
most (70%) of the main prostatic glands and it is the zone most prone to inflammation 
and prostatic carcinoma. A smaller part (25%) of the glandular tissue is located to the 
central zone. The transition zone contains the mucosal glands and cells of this zone are 
susceptible to extensive division, causing condition known as benign prostatic 
hyperplasia (BPH). The periurethral zone comprises mucosal and submucosal glands. 
Mucosal glands secrete directly into the urethra, whereas submucosal and main prostatic 
glands have ducts that open into the prostatic sinuses. (Ross and Pawlina 2006.) 
The prostatic epithelial cells secrete several components of the semen such as 
prostatic acid phosphatase (ACPP), fibrinolysin, citric acid and a serine protease 
kallikrein-related peptidase 3 (KLK3) also known as prostate-specific antigen (PSA) 
(Ross and Pawlina 2006). The prostate gland also releases sugars, sulphate and a 
vitamin E-derivative to the seamen. (Boron and Boulpaep 2009). The seminal plasma, 
which is the remainder of the semen excluding sperm cells, functions to protect the 
sperm cells in different ways. (Ross and Pawlina 2006; Boron and Boulpaep 2009 ) 
 
 
Figure 1. Location of the prostate gland in the male reproductive system (Prostate 
Health Tips 2011)  
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2.1 Testosterones 
Male steroid hormones androgens are needed for the embryonic development and adult 
function of the prostate but also the growth of prostate cancer (PC) is generally 
dependent on androgens (Miyamoto et al. 2008). Most of the androgens are produced as 
testosterone (T) by Leydig cells in the testes (Taplin and Ho 2001). Adrenal cortex also 
secretes adrenal androgens, such as androstenedione, dehydroepiandosterone (DHEA) 
and its sulphate. Adrenal androgens are not as potent as T, but they still contribute to 
androgenic effects in the body and may be further metabolized to T. Androgen 
production in the Leydig cells is regulated primarily through hypothalamic-pituitary-
gonadal axis. Gonadotropin-releasing hormone (GnRH) is secreted by the hypothalamus 
in a pulsatile manner. In the anterior pituitary GnRH stimulates the release of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH in turn 
stimulates the production of androgens in Leydig cells. Secretion of GnRH and LH are 
inhibited through negative feedback control. (Grossmann et al. 2001.) Adrenal androgen 
production is controlled through adrenocorticotropic hormone (ACTH). In the 
circulation, T is bound to serum proteins, mostly sex hormone-binding globulin 
(SHBG), albumin and corticosteroid-binding globulin. (Taplin and Ho 2001.) After 
entering the cells in the end organs, such as prostate, T is usually converted to a more 
potent dihydrotestosterone (DHT) by 5-α reductase (Grossmann et al. 2001; Taplin and 
Ho 2001). Intracellular DHT is metabolized rapidly to 3α,17β-androstenediol which can 
be converted back to DHT or to 3β,17β-androstenediol and further to water soluble, 
inactive triol steroids (Taplin and Ho 2001). 
The action of androgens is mediated by a receptor molecule, a ligand-dependent 
nuclear transcription factor, androgen receptor (AR). In an inactive form AR is bound to 
heat-shock chaperone proteins, but when androgens bind to AR, conformation of AR 
changes, it dissociates from heat-shock proteins, forms dimers and the complex 
translocates rapidly to the nucleus. There the complex binds to AR response elements 
(AREs) in DNA and affects expression of hundreds of target genes, such as KLK3 and 
ACPP. (Helenius et al. 2008.) Co-regulatory proteins are also recruited to the site and 
they too can affect gene expression of AR target genes (Taplin et al. 2004). Both T and 
DHT are capable of binding to AR, but the affinity of DHT is about two to tenfold 
compared to T making DHT the primary androgen bound by AR (Grossmann et al. 
2001).  
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3. CANCER 
Most cancers are believed to be caused by interactions between genes and the 
environment. There is evidence suggesting that tumorigenesis is a multistep process, 
each step involving genetic alterations that drive normal cells to transform into 
malignant cancer cells (Hanahan and Weinberg 2000). Cancer initiates from a single 
cell, which starts to divide uncontrollably after being damaged. Even more DNA-
alterations accumulate to daughter cells, leading to the cancer tissue gaining growth 
advantage over other cells in the surrounding environment. (Joensuu et al. 1999.) 
The best known and foundation setting alterations are mutations producing 
oncogenes and mutations inactivating tumor suppressor genes. Through these 
mutations, activated oncogenes gain the function to drive cells towards cancer cells and 
tumor suppressor genes lose their function to prevent cancer. (Hanahan and Weinberg 
2000.) In normal cells, oncogenes are in their inactivated forms and are called proto-
oncogenes. They can be activated as a consequence of DNA alteration such as mutation, 
chromosomal translocation or gene deletion or amplification. (Joensuu et al. 1999.) 
Also epigenetic factors and changes in gene expression can cause oncogene activation 
(Vogelstein et al. 2013). Alteration of only one allele can cause the oncogenic effect of 
a certain gene, but in order to cancer to develop, several genetic changes are needed. 
The function of most oncogenes is related to controlling cell growth. (Joensuu et al. 
1999.) 
In tumor suppressor genes, DNA-alteration leads to impairment of their normal 
function. Usually both alleles of the gene need to be altered in order for the cancer 
promoting effect to be generated. (Joensuu et al. 1999.) However, cancer can also 
initiate from a gene alteration in only one of the alleles, like with PTEN, as described 
later. The most common alteration causing inactivation of tumor suppressor genes is 
deletion. Inactivation can also be caused by DNA-viruses or DNA methylation. 
Products of these genes usually inhibit cell division. (Joensuu et al. 1999.)  
Cancer cells have deficiencies in regulating cell proliferation and homeostasis. Even 
though there are hundreds of different cancer types and subtypes, it is suggested that the 
malignant growth in all of them is caused by a small amount of alterations in cell 
physiology. Assuming that these changes are in common with most cancers is justified 
by the fact that the same kind of molecular mechanisms regulate cellular processes in all 
mammalian cells. (Hanahan and Weinberg 2000.) These hallmarks of cancer include 
maintaining proliferative signalling, avoiding growth suppressors, hindering cell death, 
enabling replicative immortality, inducing angiogenesis and activating tissue invasion 
and metastasis (Hanahan and Weinberg 2011) (Figure 2). 
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Figure 2: Characteristics of cancer presented by Hanahan and Weinberg (2011). 
 
Genome instability and inflammation facilitate these changes. Recent progress in 
cancer research has also introduced two potential emerging hallmarks – reprogramming 
of energy metabolism and evading immune destruction (Figure 3).  Tumor 
microenvironment also plays an important role in cancer development and progression. 
(Hanahan and Weinberg 2011.)  
 
 
 
Figure 3: Emerging characteristics and facilitating features by Hanahan and Weinberg 
                (2011). 
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4. PROSTATE CANCER 
In western countries, PC is the most frequently diagnosed cancer in men and the second 
most common cause of cancer related deaths (American Cancer Society 2011; European 
Cancer Observatory 2011). PC is strongly correlated with aging. Although 
morphological changes associated with initiation of cancer are quite common and can 
be found also in younger men, PC is usually not clinically detected until the age of 60 or 
70. (Abate-Shen and Shen 2000.) 
In addition to being a component of the seminal fluid, KLK3 more commonly 
known as PSA, can also be found in the serum of normal males in much lower 
concentrations and the amount of it in blood is often used to define the condition of the 
prostate. PSA measurements from the blood have been routinely used in detection of PC 
since 1980s. (Diamandis 1998.) However, in addition to prostate cancer, also benign 
prostatic hyperplasia (BPH) and infections can result in elevated PSA levels, so PSA is 
not a PC-specific marker (Pin et al. 2013). It has also been discovered that high- or 
intermediate-grade PC can be present in men with low PSA levels (Thompson et al. 
2004). Thus, better markers are needed for more efficient diagnosis.  
Prostate cancer lesions are often heterogeneous and multifocal. Histological 
inspections of PC tissue often show benign glands, preneoplastic (PIN) foci and 
neoplastic foci next to each other. Gleason scoring is the predominant prognostic tool 
used by pathologists. (Abate-Shen and Shen 2000.) The Gleason score is a sum of the 
most prevalent pattern grade and the second most prevalent pattern grade. Grades range 
from 1 to 5, so the sum can be from 2 to 10. A higher Gleason score means more 
advanced cancer and a bleaker prognosis for the patient. In practice, Gleason scores 
from 2 to 5 are very rarely assigned due to poor reproducibility, lack of good correlation 
with prostatectomy grade, sampling issues, and potentially misleading clinical 
implications. (Shah 2009.) The basics of the Gleason system can be seen in Figure 4. 
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Figure 4: Gleason scoring system (Epstein 2010). 
 
Gleason pattern 1 resembles normal prostate tissue the most and as the Gleason pattern 
becomes larger, the more abnormal characteristics it indicates (Ross and Pawlina 2006). 
Most PCs are quite indolent, grow relatively slow and remain confined to the 
prostate. Actually, most men diagnosed with PC will eventually die of other causes. 
Nevertheless, if the cancer is not detected early enough, or in more aggressive forms of 
PC, it can advance to invasive and metastatic stages, which usually lead to death. 
(Abate-Shen and Shen 2000.) As PC progresses, it turns from androgen dependent to 
castration-resistant PC (CRPC) during hormonal treatment. The exact mechanisms 
leading to androgen-independence remain unclear. (Best et al. 2005.)  
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4.1 Genetic changes in prostate cancer 
Previously it was thought that hereditary factors had quite small role in PCs and that 
those cases were often affiliated with early disease onset (Abate-Shen and Shen 2000). 
However, studies have given reason to believe that the effect of heritability in PC can be 
significantly higher than previously thought (up to 42 percent) (Lichtenstein et al. 
2000). In hereditary cancer, an alteration predisposing to cancer is already in a gamete 
and is thereby passed on to all the cells of the body. The gene aberration is in one allele 
and does not yet intrude the function of the cells. Cancer initiates when also the other 
allele in a certain cell gets inactivated. For this reason, hereditary cancer occurs often 
earlier in life than other cancers. The mechanisms leading to malignancy are still often 
similar and involve same genes with both types. (Joensuu et al. 1999.) 
In prostate cancer, genetic deletions have been found to occur most often in 
chromosomes 5q, 6q, 8p, 10q, 13q, 16q, 17p and 18q. Some of the target genes in these 
regions are known, such as NK3 homeobox 1 (NKX3-1) (8p) and phosphatase and 
tensin homolog (PTEN) (10q), but many are still unknown. (Saramäki and Visakorpi 
2007.) Gain-of-function alterations are less known in prostate cancer and only few have 
been identified (Taylor et al. 2010). Gains are most common in chromosomes 7p/q, 8q, 
9p and Xq and the known target genes include among others androgen receptor (AR) 
(Xq) and v-myc avian myelocytomatosis viral oncogene homolog (MYC) (8q) (Saramäki 
and Visakorpi 2007). Chromosomal aberrations at Xq (AR) (in CRPC) and 21q 
(TMPRSS2:ERG fusion) are also common (Taylor et al. 2010). 
NKX3-1 belongs to the NK subfamily of homeobox genes that are associated in cell 
differentiation and organogenesis in many species. NKX3-1 functions as a transcription 
factor and it has been shown to be very important in normal prostate development and 
function. Expression of NKX3-1 is androgen-dependent and primarily restricted to the 
prostate gland. (Bieberich et al. 1996; He et al. 1997.) The gene is located at 8p21, a 
region commonly deleted in prostate cancer and NKX3-1 expression has been shown to 
often be lost during PC progression (Bethel et al. 2006).  
PTEN, located at 10q23, is one of the most frequently mutated tumor suppressors in 
human cancer. In addition to mutations, PTEN can also be inactivated by loss of 
heterozygosity (loss of one parental copy in a chromosomal region) resulting in only 
one copy of the gene. PTEN has been found frequently deleted or mutated in prostate 
cancer cell lines and especially late stage prostate cancers. (Li et al. 1997; Cairns et al. 
1997.) PTEN is also important for embryonic development. PTEN has been shown to 
modulate cell growth, survival, migration and adhesion through its lipid phosphatase 
and protein tyrosine phosphatase activities. PTEN directly dephosphorylates two key 
tyrosine-phosphorylated proteins and thus inhibits interactions between integrins and 
extracellular matrix and integrin-triggered signalling pathways. PTEN also 
dephosphorylates a key signal transduction lipid that leads to maintaining cell 
sensitivity to apoptosis. (Tamura et al. 1999; Yamanda and Araki 2001.) 
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C-myc proteins are transcription factors that regulate genes involved in cell division, 
differentiation and apoptosis. Overexpression of MYC accelerates cell division and 
prevents differentiation. (Pelengaris et al 2002.) MYC is overexpressed in especially late 
stages of PC (Qian et al. 2002). However, the role of MYC overexpression in prostate 
cancer is not entirely clear. 
The AR is a key molecule in the initiation and growth of prostate cancer and in its 
responsiveness to hormonal therapy. The AR is located at Xq11-12, composes of 8 
exons and the full length protein contains four functional domains: an N-terminal 
regulatory domain, a DNA-binding domain, a hinge-region and a ligand binding 
domain. The N-terminus contains transcriptional activation function (TAF-1) site and 
polyglutamine (CAG) and polyglycine (GCC) repeats. Two zinc fingers in the DNA-
binding domain are needed for ARE recognition. The nuclear localization signal is in 
the hinge region. The ligand binding domain has a second transcription activation 
function (TAF-2) site and the activity to bind ligands. (Taplin and Balk 2004.) During 
prostate carcinogenesis, AR signaling pathway is suggested to be converted from 
paracrine signaling, where stromal cells regulate the growth and development of 
prostatic epithelial cells, to autocrine signaling, where AR directly stimulates the growth 
of cancer cells (Gao et al. 2001).  
AR has been found present in different stages and grades of prostate cancer from 
primary to metastatic and CRPCs (Ruizeveld de Winter et al. 1991). It was previously 
believed that CRPCs were independent of AR signalling for growth and survival (Ryan 
et al. 2010). However, it has been shown that tissue levels of testosterone and 
dihydrotestosterone remain relatively high in recurrent prostate cancer tissues despite of 
androgen deprivation therapy and enable AR signalling to continue (Titus et al. 2005; 
Ryan et al. 2010). Sufficient T and DHT tissue levels in recurrent prostate cancer have 
been hypothesized to possibly result from intracrine metabolism of circulating adrenal 
androgens or synthesis from plasma membrane cholesterol (Titus et al. 2005). 
There are different mechanisms for cancer cells to utilize low levels of androgens, 
which are present in patients during castration. Potential mechanisms include 
amplification of the AR gene or increased protein expression by other ways. The AR 
gene has been reported to be amplified in 20-30 % of CRPCs. Untreated primary 
tumors, however, do not seem to harbor AR amplifications. Samples taken from the 
same patients before and after hormonal therapy also show no amplifications prior to 
therapy and AR amplifications after treatments and recurrence. (Visakorpi et al. 1995; 
Koivisto et al. 1997.) Amplification does not fully explain the high expression levels in 
CRPC tumors and other mechanisms leading to overexpression of AR are involved 
(Linja et al. 2001). These include for example tumor suppressor protein retinoblastoma 
(RB) loss, which may induce cell cycle activating transcription factor E2F1-mediated 
deregulation of AR locus leading higher AR expression. This in turn drives progression 
to CRPC. (Sharma et al. 2010.) 
AR point mutations are found in some local and locally advanced tumors, but more 
widely in advanced androgen-independent cancers, especially after treatment with 
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antiandrogens. (Taplin et al. 1995; Tilley et al. 1996.) Most AR gene missense mutations 
in the ligand-binding domain in prostate cancer have clustered in three regions, codons 
670-678, codons 701-730 and codons 874-910. Codons 670-678 are located near the 
hinge region and mutations in that region can affect AR interactions with co-regulators. 
Codons 701-730 contain the “signature sequence”, a highly conserved loop common for 
many steroid hormone receptors. Codons 874-910 flank AF-2, which is the primary 
binding site for co-activator proteins needed for AR activity. Mutations in these areas 
affect the ligand-binding pocket and allow binding of ligands other than testosterone or 
DHT, such as other steroid hormones and pharmaceutical antiandrogens. (Buchanan et 
al. 2001; Gelmann 2002.) The most commonly found and first identified point mutation 
of AR is the T877A mutation changing threonine at position 877 to alanine. It was first 
described in LNCaP cell line. (Veldscholte et al. 1990.) The T877A mutation changes 
the stereochemistry of the binding pocket and facilitates binding of progesterone and 
other ligands (Sack et al. 2001). 
The influence of AR cofactors has been studied in prostate cancer progression. 
Levels of some cofactors, such as transcriptional intermediary factor 2 (TIF2) and 
steroid receptor coactivator 1 (SCR1) have been found to increase with increases in AR 
expression in androgen independent prostate cancers (Gregory et al. 2001). It has been 
hypothesized that overexpression of AR cofactors could make AR more responsive to 
low levels of androgen or broaden ligand specificity like mutations of AR do, but the 
confirmation of the role of AR cofactors in prostate cancer progression awaits further 
studies (Taplin and Balk 2004). 
Alternative splicing can also be one way to alter the function of AR. Three novel 
AR splice variants lacking the ligand binding domain have been found in CRPC. One of 
the isoforms, AR3 (designated by the researchers) appears to be constitutively active 
and the activity is not regulated by androgens or antiandrogens. It has seen to be up-
regulated during prostate cancer progression and the expression levels correlate with the 
risk of tumor recurrence after radical prostatectomy. It also seems to regulate some 
genes not regulated by the wild-type AR. (Guo et al. 2009.) The amount of a 
constitutively active splice variant of AR has also been shown to rapidly increase right 
after androgen deprivation. The levels of the splice variant are not high enough to 
restore the high-level AR activity in relapsed tumors, but may allow tumors to preserve 
basal AR activity needed for survival until more powerful mechanisms arise to activate 
AR. (Yu et al. 2014.) 
Gene fusions involving E-twenty-six family (ETS) genes and androgen regulated 
prostate-specific transmembrane protease, serine 2 (TMPRSS2) gene occurs in 
approximately 40-50 % of prostate cancers (Tomlins et al. 2005; Huang and Waknitz 
2009). Fusion of TMPRSS2 and ETS-family transcriptional activation factor ERG is the 
most frequent rearrangement. TMPRSS2 is constitutively expressed in prostate and the 
expression is controlled by androgens. (Paoloni-Giacobino et al. 1997; Lin et al. 1999; 
Tu et al. 2007). Several TMPRSS-ERG fusions have been identified and most of them 
involve only the 5’ untranslated region of TMPRSS2. These fusions thus cause 
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overexpression of the ERG or ETV protein induced by the TMPRSS2 promoter. (Tu et 
al. 2007.) The expression of ERG proteins also becomes androgen regulated as a 
consequence of the fusion. In prostate cancer, ERG activates WNT signaling and this 
leads to loss of cell adhesion. ERG also modulates prostate cancer prostaglandin 
signaling and affects tumor metastasis. ERG is not expressed in normal prostate tissue. 
(Wu et al. 2013.) 
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5. MIGRATION AND INVASION INHIBITORY 
PROTEIN 
The migration and invasion inhibitory protein (MIIP), also known as invasion inhibitory 
protein 45 (IIp45), was first discovered in a yeast two-hybrid screen in an attempt to 
identify binding partners of insulin-like growth factor binding protein 2 (IGFBP-2) 
frequently overexpressed in aggressive gliomas (Song et al. 2003). MIIP was found to 
bind and inhibit IGFBP-2 and other mechanisms of action related to cell migration and 
invasion have been discovered since. 
MIIP gene is located on chromosome 1p36.22, it has 10 exons and it comprises 12.6 
kb of genomic DNA (Wang et al. 2011). The transcript has 1588 base pairs. The MIIP 
protein consists of 388 amino acids with an estimated molecular mass of 43 kDa. In 
protein analysis MIIP was found to be highly hydrophilic and have three segments of 
low compositional complexity (SEG) domains and an arginine–glycine–aspartic acid 
(RGD) motif. (Song et al. 2003.) 
5.1 MIIP and cancer 
There are several factors pointing to the possibility of MIIP having a role in genesis and 
progression of cancer. First, MIIP inhibiting cancer cell migration and invasion 
promoting IGFBP-2 (Song et al. 2003). Second, the location of MIIP gene being on 
chromosome 1p36, a chromosome region known to be deleted in various cancers 
including prostate cancer, lung cancer, glioblastoma and breast cancer (Gibbs et al. 
1999; Yanada et al. 2005; Ichimura et al. 2008; Climent et al. 2010; Heinrich et al. 
2012). Many tumor-suppressor genes have been found to be located in commonly 
deleted chromosome areas. Such genes include TP53 on chromosome 17p, PTEN on 
chromosome 10 and Rb on chromosome 13. (Donehower el al 1992; Li et al. 1997; 
Burkhart and Sage 2008.)  
In addition to being deleted, tumor-suppressor genes are often found mutated. 
Although clear mutations in the MIIP gene have not been found in tissues or cell lines 
sequenced so far (Song et al. 2005, Wang et al. 2010), it does not rule out the possibility 
of MIIP being a tumor-suppressor. Tumor-suppressors can also function by other 
mechanisms, such as CHD5 and PTEN (Cairns et al. 1998; Fujita et al. 2008). In these 
cases cancer development is caused by loss of one copy of the gene without any 
mutations.  
Several single-nucleotide polymorphisms (SNPs) have also been found in different 
regions of the MIIP gene and can be found from the database of single nucleotide 
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polymorphisms, dbSNP (The National Center for Biotechnology Information 2013). 
SNPs in tumor-suppressor genes have been seen to affect cancer risk (Imyanitov 2009). 
SNPs of MIIP were investigated in a case-control study with breast cancer patients and 
healthy women and SNP rs2295283 was found to affect breast cancer risk. SNP 
rs2295283 has two variants; adenosine (A) and guanine (G) and they result in two 
different amino acids, lysine (Lys, K) or glutamic acid (Glu, E) at codon 167. Presence 
of G allele was found to be a protective factor for breast cancer in both AG (one A allele 
and one G allele) and GG (both G alleles) genotypes when compared with the AA 
genotype. Glu amino acid at codon 167 was associated with lower risk of breast cancer, 
but also to smaller and lower-grade tumors. (Song et al. 2010.) 
Expression of MIIP has been shown to inhibit glioma cell invasion both in vitro and 
in vivo. Correspondingly, in glioma tissues including highly invasive glioblastoma 
multiforme, expression of MIIP has been seen to be reduced. (Song et al. 2003.) In 
addition, MIIP is alternatively spliced in gliomas. Alternative splicing produces an 
unstable isoform of the protein and the frequency of it correlates with glioma grade. 
(Song et al. 2005.) 
 
5.2 Mechanisms of action of MIIP 
5.2.1 Insulin-like growth factor binding protein 2 
MIIP has been found to bind and inhibit IGFBP-2 (Song et al. 2003). As part of the 
insulin-like growth factor (IGF) network, insulin-like growth factor binding proteins 
(IGFBPs) are important in regulating cell proliferation, differentiation, migration, 
survival and metabolism (Duan and Xu 2005). IGFBP-2 has also been found to be 
overexpressed in several cancers including glioblastoma multiforme, prostate, ovarian, 
breast and colon cancers (Kanety et al. 1993; Fuller et al. 1999; Renehan et al. 2000; 
Busund et al 2005; Wang et al 2006). 
In addition to its effects on IGFs, IGFBP-2 has also been shown to specifically bind 
to the α5β1 integrin on the cell surface with its RGD-motif and promote de-adhesion of 
tumor cells (Schütt et al 2004). Integrins affect signalling through integrin-linked kinase 
(ILK), which binds to β1 and β3 integrins. ILK stimulates invasion and migration and 
induces tumor angiogenesis. IGFBP-2 has been shown to be connected to the 
integrin/ILK/NF-κB network. IGFBP-2 was seen to activate integrin β1 and its 
downstream pathways, require ILK for cell migration and to activate NF-κB, a 
transcriptional factor, which activates the transcription of many cancer-promoting 
genes. Blocking any constituent of the integrin/ILK/NF-κB network also hindered 
progression of gliomas driven by IGFBP-2 in vivo. (Holmes et al. 2012.) IGFBP-2 has 
also been discovered to contribute to glioma progression by promoting tumor cell 
invasion through increased matrix metalloproteinase-2 (MMP-2) transcription (Wang et 
al. 2003). 
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In addition, it has been shown that IGFBP-2 has an inhibitory effect on non-
malignant prostate cells, but for DU145 and LAPC-4 prostate cancer cells the effect is 
stimulatory in a mitogen-activated protein (MAP) kinase and androgen-modulated 
process. This suggests that there could be a molecular switch conversing IGFBP-2 from 
growth inhibitor to tumor promoting molecule. (Moore et al 2003.) 
In an invasion study with BioCoat Matrigel invasion chamber, LN-229 cells were 
transfected with MIIP, IGFBP-2 or MIIP+IGFBP-2. The invasiveness of MIIP-
expressing cells decreased by approximately 50 %, whereas that of IGFBP-2-expressing 
cells increased approximately 250 %, when compared with the invasiveness of cells 
transfected with control vector. Invasion was also attenuated in cells transfected with 
both MIIP and IGFBP-2, compared with cells expressing only IGFBP-2. (Song et al 
2003.) 
MIIP was found to bind to the same thyroglobulin-RGD region of IGFBP-2 that is 
also utilized in IGFBP-2 binding to integrin α5 (Song et al. 2003). Therefore binding of 
MIIP to IGFBP-2 could inhibit IGFBP-2 from binding to integrin and interfere with the 
downstream pathways (Wang et al. 2011). 
 
5.2.2 Histone deacetylase 6 
By using MIIP as a bait molecule in a yeast two-hybrid assay, Wu et al. found MIIP to 
bind to histone deacetylase 6 (HDAC6) (Wu et al. 2010). HDAC6 is a cytoplasmic 
enzyme that deacetylates α-tubulin, heat-shock protein 90 (Hsp90) and cortactin, and 
forms complexes with other partner proteins. Through these actions HDAC6 regulates 
many important biological processes such as cell migration. (Valenzuela-Fernandez et 
al. 2008.) HDAC6 possesses two functional deacetylase domains, which are both 
needed for intact enzymatic activity (Zhang et al. 2006)  and a zinc finger motif that 
could be involved in regulating ubiquitination (Seigneurin-Berny et al. 2001). 
Reversible acetylation of α-tubulin, an important component of the cytoskeleton, 
regulates microtubule stability and function and thus affects cell motility (Hubbert et al. 
2002).  
MIIP binds to both catalytic domains of HDAC6. Overexpression of MIIP and 
knockdown of HDAC6 was seen to cause increased levels of α-tubulin acetylation, 
whereas transfection with MIIP small interfering RNA (siRNA) decreased α-tubulin 
acetylation. This strongly suggests that MIIP inhibits deacetylase activity of HDAC6. 
MIIP was also found to reduce the protein stability of HDAC6. Through these 
mechanisms MIIP increases acetylation of α-tubulin and decreased cell motility. (Wu et 
al. 2010.) 
Cortactin is another protein that has an important role in regulating cell motility. Its 
interaction with F-actin promotes polymerization and branching of the actin assembly. 
The acetylation status of cortactin influences its F-actin binding activity. (Zhang et al. 
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2007.) MIIP could inhibit cell migration also by decreasing HDAC6 mediated 
deacetylation of cortactin (Wu et al. 2010). 
Hsp90 is a molecular chaperone that interacts with a large number of client proteins 
and regulates signal transduction pathways. Acetylation of Hsp90 is one of the 
regulators of Hsp90 activity. (Li et al. 2012.) When Hsp90 is inhibited, tyrosine 
phosphorylation of focal-adhesion kinase (FAK) and assembly of focal adhesions are 
reduced and further FAK-dependent actions such as actin cytoskeleton rearrangement, 
cell migration and cell invasion are inhibited (Rousseau et al. 2000; Masson-Gadais et 
al. 2003; Koga et al. 2007). Thus, inhibition of cell migration by MIIP may also 
function through deacetylation of Hsp90 by HDAC6 (Wu et al. 2010). 
 
5.2.3 Mitosis 
In normal conditions, cell cycle is tightly controlled by numerous regulatory elements 
and molecules. Cells go through the phases of cell cycle G1, S, G2 and finally M in a 
highly orchestrated manner and disruption of this balance may lead to different diseases. 
MIIP may also have an important role in regulation of mitosis. In flow cytometry 
analysis, MIIP expression was shown to markedly delay G2/M transition in the cell 
cycle in LN229 cells. MIIP was discovered to bind to cell division cycle protein 20 
(Cdc20), a molecule that activates anaphase-promoting complex/cyclosome (APC/C) 
ubiquitin-ligase E3. (Ji et al. 2010.) APC/C allows ubiquitination and degradation of 
securing and cyclin B1 which in turn contributes to mitotic exit (Yu 2007). A significant 
decrease in an APC/C substrate cyclin B1 ubiquitination was observed in the presence 
of MIIP, implying that the interaction of MIIP and Cdc20 causes reduction in APC/C 
ubiquitin-ligase activity. Cyclin B1 protein levels were also seen to positively correlate 
with levels of MIIP in several cancer cell lines, indicating that MIIP modulates cyclin 
B1 stability. MIIP expression in LN229 glioma cells was connected to increased 
chromosomal abnormalities and mitotic catastrophe. (Ji et al. 2010.) 
MIIP might regulate mitosis also through its previously described effect on HDAC6 
mediated α–tubulin acetylation (Wang et al. 2011). Microtubules consisting of the αβ–
tubulin heterodimers form the mitotic spindle during cell division and facilitate the 
separation of replicated sister chromatids. Microtubules also function in aiding the 
intracellular organelle and vesicle transportation. Acetylation of α-tubulin has a role in 
regulating these functions. (Westermann and Weber 2003.)  
 
5.2.4 Other 
In an attempt to find genes associated to expression of MIIP, a cDNA microarray 
expression profiling was made and several adhesion- and motility-associated genes were 
seen to be downregulated in cells expressing MIIP. Among them were integrin αL/β8, 
cell division cycle protein 42 (Cdc42), transcription factor nuclear factor kappa B 
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(NFκB) and its target genes intracellular adhesion molecule 1 (ICAM-1), interleukin 10 
(IL-10) and E-selectin (SELE). (Song et al. 2003.) However, it remains unclear how and 
how much MIIP affects these gene expressions. 
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6. PROSTATE CANCER TREATMENT 
6.1 Clinically localized prostate cancer 
Treatment methods for clinically localized prostate cancer currently include active 
surveillance (AS), radical prostatectomy, external-beam radiation therapy, and 
interstitial radiation therapy (brachytherapy) (Heidenreich et al. 2012). Active 
surveillance is an option for men with low-risk prostate cancer. It builds upon the 
assumption that in low-risk disease, the time between diagnosis and clinical progression 
is usually long, so men with diagnosed low-risk prostate cancer will not necessarily 
have any clinical symptoms of the condition during their lifetime. Men are not treated 
with anything, but are closely followed by serial PSA assessments, repeat biopsies, and 
possible other tests to identify early signs of progression. At the first signs of higher-risk 
disease, treatment is initiated. (Klotz 2010; Klotz 2012.) 
The gold standard in the surgical management of localized prostate cancer is radical 
prostatectomy (Mullins et al. 2012). The goal of radical prostatectomy is to remove all 
of the carcinoma tissue. The operation can be done as an open surgery or 
laparoscopically either manually or using robot-assisted techniques. All options have 
been found to be safe presenting similar overall complication rates. (Coelho et al. 2010.) 
Pelvic lymph nodes can be removed in the same surgery (El-Galley et al. 2002). 
Disease-specific mortality, overall mortality, and the risks of metastasis and local 
progression have been proven to be reduced with radical prostatectomy. Though the 
reduction in the risk of death after 10 years is small, the reductions in the risks of 
metastasis and local tumor progression are significant. (Bill-Axelson et al. 2005). 
However, radical prostatectomy can cause side-effects such as erectile dysfunction and 
urinary leakage, which have an impairing effect on quality of life after surgery (Steineck 
et al 2002). 
If surgical intervention is not possible or not wanted, another option is radiation 
therapy. Radiation therapy can also be given as adjuvant treatment after prostatectomy 
when the risk of recurrence is high. Three-dimensional conformal radiotherapy (3D-
CRT) is widely used but newer techniques like intensity-modulated radiotherapy 
(IMRT) and image-guided radiotherapy (IGRT) are also becoming more common. 
(Heidenreich et al. 2012.)  
It has been stated that the dose of external radiotherapy should be at least 74 grays 
(Gy) because biochemical disease-free survival is significantly higher when compared 
with a dose <72 Gy (Hayden et al. 2010). Studies have shown that higher, up to 78 Gy 
doses result in a significant improvement in freedom from failure for patients with 
intermediate to high risk tumors. However, escalated doses also increase the incidence 
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of rectal side effects, so techniques preventing radiation to the surrounding tissues are 
preferable. (Pollack et al. 2002.) In addition to the prostate gland, seminal vehicles are 
often also treated. Seminal vehicles can be given the same dose as the prostate gland or 
they can be left outside the treatment area after 45-50 Gy. (Prostate cancer: Current 
Care Guidelines 2007.) Pelvic lymph nodes can also be radiated at a dose of 45-50 Gy 
when there is a high risk for lymph node metastasis (Roach et al 2006). 
IMRT allows delivery of higher doses of radiation with very low toxicity and lesser 
side-effect (Vora et al. 2007). IMRT is delivered using a multileaf collimator (MLC) to 
shape the particle beams (Luxton et al. 2004). 
In IGRT the exact position of the prostate is being located with the help of imaging 
methods. Different methods such as rectal balloon catheters, fiducial markers (e.g. 1mm 
diameter gold seeds), three-dimensional ultrasound and computer tomographic imaging 
can be used. When the precise location is known, smaller margins can be used and 
radiation to normal tissues can be reduced. (Button and Staffurth 2010.) 
Increasing the radiation dose alone is not enough for high-risk PC and adjuvant 
androgen deprivation therapy (ADT) is used for 3 years. For high-risk PC, a short 
course of neoadjuvant hormonal ablation can also be applied for 2 months before as 
well as during radiotherapy. (Heidenreich et al. 2012.) The principle of ADT in more 
detail is explained in the following chapter. 
For low-risk PC, low dose rate (LDR) prostate brachytherapy can also be used 
(Heidenreich et al. 2012). In LDR brachytherapy radioactive seeds are delivered into the 
prostate using transrectal ultrasound imaging guidance. Radioisotopes can be either 
Iodine-125 (I-125) or Palladium-103 (Pd-103). (Machtens et al. 2006.) Finnish centers 
use I-125 (Prostate cancer: Current Care Guidelines 2007). The half-life of I-125 is 60 
days and it has an energy of 0.028 keV. 100-120 Gy is generally delivered in 2 Gy 
fractions. (Machtens et al. 2006.) In Finland, a dose of 140 Gy is used (Prostate cancer: 
Current Care Guidelines 2007). Good long-term results have been achieved with LDR 
brachytherapy (Taira et al. 2011). 
Cryosurgical ablation has been considered as a treatment method, but while there 
are no reliable long-term results, it is not in the official treatment recommendations 
(Heidenreich et al. 2012). In cryosurgical ablation, liquid nitrogen is used to freeze the 
prostate or areas of it using ultrasound guidance (Babaian et al. 2008). 
Several studies have shown that patients with localized disease do not benefit from 
added antiandrogen bicalutamide. However, adding bicalutamide to standard care 
results in considerable clinical benefits in patients with locally advanced prostate 
cancer. (McLeod et al. 2006; See et al. 2006.) 
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6.2 Advanced and castration resistant prostate cancer 
6.2.1 Traditional treatment methods 
Endocrine treatment of prostate cancer aims to deprive the cancer cells of androgens. 
This can be executed by eliminating the testosterone production of the testes or by 
blocking the androgen receptors (AR) with antiandrogens (Tammela 2012). The first 
method of permanent testosterone synthesis prevention was bilateral orchiectomy 
(surgical removal of the testes) and reversible castration was first achieved with 
estrogen treatment (Huggins and Hodges 1941). Charles B. Huggings received a Nobel 
Prize price for his discoveries concerning hormonal treatment of prostatic cancer in 
1966. 
Orchiectomy is still considered the primary option for ADT in cases related with 
high spinal cord compression risk, brain metastasis or severe pain (Prostate cancer: 
Current Care Guidelines 2007). Medically castration can be achieved with 
gonadotropin-releasing hormone (GnRH) (often used as a synonym of luteinizing 
hormone-releasing hormone (LHRH)) agonists and antagonists of which LHRH 
agonists represent the standard care (Tammela 2012; Heidenreich et al. 2013). 
Castration with oestrogen agonists has widely been abandoned due to unwanted side 
effects (Prostate cancer: Current Care Guidelines 2007; Tammela 2012). 
Continuous stimulation of the pituitary with high concentrations of GnRH agonist 
causes receptor desensitization and inhibition of LH release, which further blocks 
testosterone synthesis by the testes. GnRH agonists available include for example 
goserelin, leuprorelin, buserelin and tritorelin. During first 1-2 weeks of GnRH agonist 
therapy, there is an increase in LH production and plasma testosterone levels, referred 
often as the flare effect. Therefore, co-treatment with antiandrogen is used for 2-3 
weeks from the initiation of GnRH agonist treatment. (Tammela 2012.) GnRH 
antagonists on the other hand rapidly block the release of both LH and FSH resulting in 
more rapid and crucial decrease in serum testosterone level without the flare effect 
(Tammela 2012). GnRH antagonists have proven useful in patients with locally 
advanced or metastatic disease, but the benefits in other situations remain to be verified 
(Heidenreich et al 2013). Intermittent androgen deprivation (IAD) in which androgen 
blockade and treatment cessation alternate to enable hormonal recovery between cycles 
has been tested to improve tolerability and quality of life. Meta-analysis of 13 trials 
comprising 6419 patients showed that overall survival, time to progression and quality 
of life were similar in IAD and continuous androgen deprivation. However, patients 
treated with IAD had lower incidence of hot flushes and higher sexual activity scores. 
(Botrel et al 2014.) 
In maximum androgen blockade (MAB), the action of testosterone is inhibited by 
preventing the production by the testes using castration, and by blocking AR by 
antiandrogens to inhibit the effects of adrenal and locally produced androgens 
(Tammela 2012). However, MAB provides only small survival advantage compared 
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with GnRH agonist monotherapy and is associated with significant impairment of 
quality of life (Heidenreich et al. 2013). 
There are steroidal and non-steroidal antiandrogens and they can be used as 
monotherapy or in combination with castration. Antiandrogens competitively inhibit the 
binding of DHT and testosterone to AR. Steroidal antiandrogens (cyproterone acetate) 
also binds to progesterone receptors in the pituitary inhibiting the release of LH and 
production of testosterone by the testicles. However, steroidal antiandrogens have been 
seen to cause more adverse effects than GnRH agonists and non-steroidal antiandrogens 
such as bicalutamide, flutamide and nilutamide. Currently, bicalutamide is the best 
tolerated antiandrogen. Bicalutamide offers benefits in quality of life, so bicalutamide 
has been considered as an option to castration for younger, sexually active men with 
locally advanced prostate cancer. (Tammela 2012.) However, clinical benefits are minor 
or nonexistent and therefore bicalutamide monotherapy is not recommended as a 
standard care (Heidenreich 2013). 
All types of endocrine treatment have adverse events which influence quality of life 
in different ways. The proper use and timing of endocrine therapy still remain subjects 
of debate. (Tammela 2012). 
In case of recurrence, local recurrences are often treated by salvage radiation 
therapy with 64-66 Gy. High-intensity focused ultrasound (HIFU) or cryotherapy have 
also been proposed as an alternative because of equal efficacy but less morbidity. 
(Heidenreich et al. 2013.) With metastatic CRPC, life-expectancy is short, only about 
one and a half years, and treatment often aims in alleviating the symptoms and 
improving quality of life (Prostate cancer: Current Care Guidelines 2007). 
Chemotherapy with docetaxel can be used for metastatic CRPC. Docetaxel is a 
semi-synthetic taxane which functions by disrupting the function of cellular 
microtubules and thus preventing cell division (Shelley et al 2006). It can offer pain 
relief and improve quality of life compared to other treatments and also extend life 
expectancy (Tannock et al 2004).  New and improved agents have also been developed 
and they are becoming more widely used. 
6.2.2 Newer treatment methods 
Although orchiectomy and chemical castration effectively block androgen synthesis 
of the testes, androgen synthesis still continues in adrenals and tumor cells resulting in 
adequate levels of androgens in the prostate to stimulate PC cell growth (Titus et al. 
2005). Abiraterone is a selective cytochrome P450 c17 (CYP17) inhibitor. CYP17 is a 
crucial enzyme in androgen biosynthesis despite production location, so abiraterone 
blocks androgen synthesis of adrenals and tumor cells in addition to that of testes. (de 
Bono et al. 2011.) Abiraterone also significantly increases adrenocorticotropic hormone 
(ACTH) levels and plasma levels of 11-deoxycorticosterone and corticosterone, leading 
to unwanted effects such as hypokalemia, hypertension and edema. These are 
suppressed by co-administration of a synthetic glucocorticoid. (Attard et al. 2008.) 
Abiraterone has also been found to reduce AR protein expression and R1881-induced 
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AR transactivation in prostate cancer cell lines, which may influence the anti-tumor 
effects (Solifer et al 2012). In patients with metastatic CRPC previously treated with 
chemotherapy, overall survival was seen to be longer with abiraterone compared to 
placebo (14.8 months vs. 10.9 months) (de Bono et al 2011). 
More effective AR antagonists have been developed to overcome issues related to 
first generation antagonists. First generation AR antagonists such as bicalutamide and 
flutamide have lower affinity to AR than DHT and they demonstrate partial antagonism, 
which leads to weak results especially when AR is highly overexpressed (Chen et al. 
2004). The AR affinity of the second generation AR antagonist enzalutamide is 8-fold 
higher than that of bicalutamide and no agonism is shown. Enzalutamide inhibits AR 
translocation into nucleus and impairs its DNA binding and co-activator recruiting, but 
also induces apoptosis in VCaP cells which have AR gene amplification. (Tran et al. 
2009.) Enzalutamide was seen to extend the survival of men with metastatic CRPC 
previously treated with chemotherapy. In the ezalutamide group, the median overall 
survival was 18.4 whereas in the placebo group it was 13.6 months. (Scher et al 2012.) 
Cabazitaxel belongs to taxanes like docetaxel and acts with the same mechanism by 
binding to tubulin and inhibiting microtubule depolymerization and consequently 
arresting mitosis. Cabazitaxel demonstrates greater antitumor activity and can be used 
also in docetaxel-resistant cancers. (Mita et al 2009; de Bono et al. 2010.) Cabazitaxel 
has a lower affinity for P-glycoprotein, the drug efflux pump responsible for multidrug 
resistance, which may affect the better antitumor properties (Mita et al. 2009). 
Cabazitaxel was found to improve overall survival in patients with metastatic castration-
resistant prostate cancer whose disease has progressed during or after docetaxel 
treatment. The median survival was 15.1 months in the cabazitaxel group and 12.7 
months in the mitoxantrone (control) group. Median progression-free survival was 1.4 
months higher in the cabazitaxel group than in the mitoxantrone group. (de Bono et al. 
2010.) 
Several gene therapy approaches have been proposed as possible treatment methods 
for prostate cancer. The anatomy and biology of the prostate gland allow prostate cancer 
to be an extremely powerful candidate for gene therapy. The prostate gland is not an 
essential organ so its complete removal or ablation is possible. In addition, it can be 
easily accessed for implantation of therapeutic agents or taking tissue samples. A 
number of genes, including KLK3, h-kallikrein-2, prostate specific membrane antigen, 
probasin and relaxin H2, are also specifically expressed in prostate tissue under tight 
control of tissue specific promoters. The osteocalcin gene encoding a major 
noncollagenous bone protein is also overexpressed in prostate cancer. These facts can 
be used in targeting the expression of therapeutic genes selectively to prostate cancer. 
(Harrington et al. 2001.) 
In gene therapy, a functional gene can be introduced to the target tissue to restore 
absent or deficient protein production, to modulate the immune system or to destroy 
cells in a controlled manner to slow down the disease (Kootstra and Verma 2003).  
Although the principle of gene therapy is relatively simple, one major problem has been 
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efficient delivery of the gene to the target tissue (Verma and Weitzman 2005). Viral and 
non-viral vectors can be used for gene delivery purposes. Viral vectors are more popular 
in clinical trials at the moment and of those adenoviral vectors are most widely used 
(Gene Therapy Clinical Trials Worldwide 2011). Other viral vectors used for gene 
delivery include retroviral vectors, poxvirus vectors, adeno-associated virus vectors and 
herpes simplex virus vectors (Harrington et al. 2001; El-Aneed 2004). Common non-
viral vectors include naked DNA injections, cationic polymers, cationic peptides, 
cationic lipids and cells (Harrington et al. 2001; El-Aneed 2004; MacRae et al. 2006; 
Kitchen et al. 2011). 
Gene therapy for cancer can be divided into three main categories: immunotherapy, 
oncolytic virotherapy and gene transfer. The purpose of immunotherapy is to strengthen 
the immune system to attack and destroy the cancer cells. Cancer vaccines are an 
example of immunotherapy. (Cross and Burmester 2006.) In oncolytic virotherapy 
oncolytic virus (OV) vectors are used in destroying the tumor. Oncolytic viruses are 
able or can be modified to replicate specifically in cancer cells and cause their death as a 
consequence of the lytic viral cycle. Due to targeting to cancer cells, normal cells of the 
body remain intact. (Mullen and Tanabe 2002.) In gene transfer, a foreign gene is 
introduced into the cancer cells or the surrounding tissues. Genes with several different 
functions can be used, including genes causing cell death when expressed (suicide 
genes), antiangiogenesis genes, genes that restore the function of a deleted or mutated 
gene (often a tumor suppressor gene), genes that negate the effect of a tumor promoting 
gene (oncogene) or genes that enhance immune responses against tumor tissues. 
(Harrington et al. 2001; Cross and Burmester 2006.) 
Sipuleucel-T is one example of a successful gene therapy approach in prostate 
cancer. It is a cancer vaccine containing autologous peripheral-blood mononuclear cells 
(PBMCs); including antigen-presenting cells (APCs), that have been activated ex vivo 
with a recombinant fusion protein (PA2024). In PA2024, a prostate antigen, prostatic 
acid phosphatase (ACPP) is fused to granulocyte–macrophage colony-stimulating factor 
(GM-CSF). (Kantoff et al. 2010.) GM-CSF activates the APCs and ACPP works as the 
target antigen and navigating epitope. Back in the body, sipuleucel-T induces an 
immune response to ACPP, which is one of the major proteins secreted by prostate. 
ACPP serum levels are also significantly elevated in many metastatic prostate cancers. 
(Provenge: EPAR – Public assessment report 2013.) Sipuleucel-T was found to reduce 
the risk of death significantly compared to placebo in men with advanced prostate 
cancer (Higano et al. 2009; Kantoff et al 2010). 
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7. CELL LINES AND XENOGRAFTS AS 
PROSTATE CANCER MODELS 
One of the biggest obstacles to gaining more biological information about prostate 
cancer and developing drugs to fight it has been the paucity of adequate model systems. 
Prostate cancer is very heterogeneous morphologically and molecularly, it grows 
relatively slowly and is highly dependent on paracrine and endocrine signaling. Due to 
all this, it has been very challenging to grow human prostate cancer in the laboratory in 
vitro or in vivo. (Pienta et al. 2008.) 
Xenografts are widely used models in cancer research and drug development. 
Prostate cancer xenografts can be established by implanting surgically removed human 
prostate cancer explants into immunodeficient mice. The tissue can be from primary 
tumors or from metastatic sites and also prostate cancer cell lines can be used. However, 
xenografts from primary tumors are extremely difficult to carry out. (Chauchereau 
2011.) Xenografting is usually done to the three major graft sites; subcutaneous, under 
the renal capsule and orthotopic. Orthotopic xenograft model is achieved by implanting 
human prostate tumor cells into mouse prostate glands. Different graft sites have their 
advantages and disadvantages. (Wang et al.2005) 
The subcutaneous site has been the most commonly used because it can be easily 
accessed and large amounts of tumor can be grafted there. However, vascularization is 
relatively poor and especially with primary tumors the survival rates are low. The 
subrenal capsule has proven relatively successful with different tissue types, especially 
with primary tissues including localized prostate cancer. The vascularization under the 
renal capsule is high, assuring sufficient amount of nutrients to the tumor prior to 
developing their own vasculature. Yet, the surgery is more difficult and less tissue can 
be transplanted under the renal capsule than subcutaneously. Different approaches such 
as maintaining host androgen levels by implanting testosterone and precision cutting of 
tissue slices have been tested to achieve better survival rates. (Wang et al. 2005; Zhao et 
al. 2010.) Orthotopic graft site has the advantage of having similar microenvironment as 
the original tumor site and orthotopic xenografts seem to also mimic the actual disease 
better (Chauchereau 2011). Survival rate of grafts is lower than with subrenal graft site, 
but the proportion of glands in every surviving graft seems to be higher. However, 
rodent prostate is not very easily accessible and the capacity to carry xenografts is 
limited. (Wang et al. 2005) 
After implantation and tumor growth, it can be serially transplanted into other 
animals. Xenografts are able to retain various biological properties of the original 
human tumors they are derived from, but the major disadvantage of these models is the 
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need for continuous transplantation in animals and due to high transplantation failure 
rate, a large number of animals is needed, which is both expensive and laborious. 
(Chauchereau 2011.) Immunodeficient hosts are required for xenografting so that the 
host does not reject the transplanted tissue. Either athymic or severe combined 
immunodefiency (SCID) animals can be used.  Athymic animals lack a thymus and are 
unable to produce T-cells, whereas SCID is a genetic disorder. However, the absence of 
an immune system is not a normal situation with prostate cancer patients and it should 
be considered when applying results achieved with this type of model to practice. 
(Wang et al. 2005.) Ethical issues may also cause concern. 
The advantages of in vitro cell cultures are relatively low costs and high replicative 
capacity ensuring enough material for long-term use. They offer a simple approach to 
study cell behavior and molecular pathways involved in PC. However, the biological 
properties of the original cancer tissue are not well preserved in in vitro two-
dimensionally cultured cell lines. (Sampson et al 2013.) Immortalized cell lines can also 
harbor genetic alteration and mutations that are not typical for the original disease. The 
loss of AR and KLK3 is a common characteristic for several cell lines. (Peehl 2005). 
Most of the PC cell lines are derived from advanced or metastatic disease and same few 
most common cell lines are used for most experiments. This hinders the study of earlier 
stages of PC and lacks diversity normally seen in human prostate cancer. (Peehl 2005; 
Pienta et al. 2008.) Nevertheless, the usefulness of these models is proven by our 
continuously increasing knowledge of molecular mechanisms regulating PC 
development and progression. Development of three-dimensional co-culture systems 
has also given new extent to investigation of stromal-epithelial interactions, 
angiogenesis and metastasis. Several in vitro models have been created and each model 
system has its own characteristics. (Sampson et al 2013.) However, developing these 
cell lines is anything but simple and there are very few models available for PC despite 
the fact that PC is a common cancer. 
LNCaP, PC3 and DU145 were the first human prostatic tumor epithelial cell lines 
established and they are still the most commonly used PC cell lines (Sampson et al 
2013). LNCaP cells have been derived from lymph node metastasis of human prostate 
adenocarcinoma. They are androgen responsive and DHT regulates their proliferation. 
LNCaP cultures also produce acid phosphatase and KLK3. (Horoszewicz et al. 1983.) 
LNCaP cells express AR that carries the T877 mutation in the AR ligand binding 
domain changing threonine 877 with alanine which affects both binding specificity and 
the induction of gene expression (Taplin et al. 1995). LNCaP is widely used for 
studying AR signalling in prostate cancer. PC3 cells are established from bone 
metastasis and DU145 cells from brain metastasis and neither of these cell lines 
responds to androgens. (Sampson et al. 2013.) 
In addition to these most commonly used cell lines established directly form tissues 
of PC patients, there are several cell lines derived from human PC tissue first 
heterotransplanted into immune-deficient mice. Such cell lines include VCaP and 
DuCaP that were established from bone and brain metastasis of the same patient with 
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CRPC by xenografting them first into SCID mice and harvesting them later for in vitro 
culture. Both cell lines are sensitive to androgens and express wild-type AR. In 
addition, they harbour the TMPRSS2:ERG fusion and high level AR gene amplification. 
(Saramäki et al. 2008; Sampson et al. 2013.) The LAPC cell lines were established with 
the same principle from eight different patients (Sampson et al. 2013). LAPC-4 
expresses wild-type AR, KLK3 and HER-2/neu receptor tyrosine kinase and it has been 
used for example to compare drug efficacy with cell lines expressing mutated forms of 
AR (Cherian et al. 2012; Craft et al. 1999; Sampson et al. 2013). 22Rv1 is a cell line 
derived from a xenograft that was serially propagated in mice after castration-induced 
regression and relapse of the parental, androgen-dependent CWR22 xenograft 
(Sramkoski et al 1999). 22Rv1 cells secrete KLK3 and express AR, but in lower levels 
than LNCaPs. 22Rv1s also carry a H874Y mutation in AR, which results in change in 
codon 874 from CAT for histidine to TAT for tyrosine and leads to reduced specificity 
of AR. (Attardi et al. 2004.) In addition, these cells harbour two distinct forms of AR, a 
larger one with an extra zinc finger motif and a C-terminally truncated one (Sampson et 
al. 2013). 
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8. MATERIALS AND METHODS 
8.1 Cell lines and xenografts 
DU145, LNCaP, PC3 and 22Rv1 cell lines used in the research were obtained from 
American Type Cell Collection (Manassas, VA, USA). VCaP and DuCaP cell lines 
were kindly provided by Dr. Jack Schalken (Radboud University Nijmegen Medical 
Center, Nijmegen, the Netherlands) and LAPC-4 cell line by Dr. Charles Sawyers 
(University of California, Los Angeles, CA, USA). All cell lines were stored in liquid 
nitrogen and cultured under recommended conditions. 19 previously established 
LuCaP-xenografts (Royai et al. 1996) were available for the analyses by collaboration 
with Professor Vessella (University of Washington, Seattle, WA, USA). All samples 
were snap frozen in liquid nitrogen and stored at -80ºC. 
8.2 Plasmids and siRNAs 
pCMV6-AC-HA expression vector inserted with MIIP coding region was kindly 
donated by Wei Zhang (The University of Texas MD Anderson Cancer Center, 
Houston, USA) and verified by PCR and sequencing. PCR for plasmids containing 
MIIP was done using Dynazyme II DNA polymerase (Thermo Scientific, Thermo 
Fisher Scientific, Inc., Waltham, USA) and specially designed primers (sequences can 
be found from Table 4). Reaction volume of 25 µl was used. 20 nanograms of plasmid 
DNA was used in each reaction and manufacturer’s protocol was followed with the 
exceptions of not adding any MgCl2 to the reaction mix and using slightly modified 
denaturation times and temperatures (Table 1). 
 
Table 1: Dynazyme PCR reactions 
 
Cycle step Temperature Time Cycles 
Initial denaturation 95ºC 5 minutes 1 
Denaturation 95ºC 30 seconds  
35 Annealing 56ºC 30 seconds 
Extension 72ºC 60 seconds 
Final extension 72ºC 10 seconds 1 
Cooling 4ºC hold 1 
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PCR-products were run on 1 % agarose gel and visualized with ethidium bromide and 
the size of the PCR product was verified. MIIP gene was also sequenced from the 
plasmid according to the sequencing protocol described later. 
To generate a control vector, the insert was digested with EcoRI and MluI restriction 
enzymes and the empty plasmid was isolated from agarose gel. The empty plasmid was 
purified with QIAquick Gel Extraction Kit (Qiagen, Venlo, Netherlands) according to 
the manufacturer’s protocol. The ends of the plasmid were blunted with Klenow’s 
fragment (Fermentas Inc., Burlington, Ontario, Canada) and ligated together with T4 
ligase (New England Biolabs Inc., Ipswich, MA) according to manufacturer’s protocols. 
One Shot
®
 chemically competent TOP10 E. coli cells (Invitrogen Life Technologies, 
Carlsbad, CA) were transformed with pCMV6-AC-HA-MIIP- and empty pCMV6-AC-
HA- plasmids using heat-shock transformation according to manufacturer’s instructions. 
Cells were cultured overnight on LB plates containing ampicillin and individual 
colonies were further grown in suspensions to achieve sufficient amount of plasmids for 
transfections. Plasmids were isolated from the bacterial culture using Qiagen plasmid 
Maxi Kit (Qiagen, Venlo, Netherlands) according to manufacturer’s protocol. 
Commercially available small interfering RNAs (siRNAs) SI00392000 (named 
MIIP siRNA1 during the study), SI00392007 (MIIP siRNA2), SI00392014 (MIIP 
siRNA3) and SI04271365 (MIIP siRNA4) for MIIP (Qiagen, Venlo, Netherlands) were 
used in siRNA transfections. AllStars Negative Control siRNA SI0650318 (Qiagen, 
Venlo, Netherlands) was used as a control. 
 
8.3 Cell culture and transfections 
DU145 and LAPC-4 cells were maintained, respectively, in DMEM and IMDM (Lonza, 
BioWhittaker
®
, Basel, Switzerland) supplemented with 10% and 15% fetal bovine 
serum (FBS; Lonza, BioWhittaker
®
, Basel, Switzerland) and 1% L-glutamine (Lonza, 
BioWhittaker
®
, Basel, Switzerland) and incubated in a humidified incubator at 37°C 
with 5% CO2.  
Plasmid transfections were performed using Lipofectamine LTX and Plus reagents 
and their protocol (Invitrogen Life Technologies, Carlsbad, CA). Briefly, DU145 cells 
were plated 50 000 cells per well on 24-well plates and transfected 2 days later when 
cells were approximately 70% confluent. For each well, 0.5 µg of plasmid DNA was 
diluted into 100 µl of Opti-MEM I Reduced Serum Medium without serum. PLUS 
reagent was gently mixed and 0.5 µl of PLUS reagent per every 0.5 µg of DNA was 
added to the diluted DNA. Solution was gently mixed and incubated at room 
temperature for 5 minutes. For each well 1.5 µl of Lipofectamine LTX reagent was 
added to the diluted DNA solution, mixed gently and incubated at room temperature for 
25 minutes to form DNA-Lipofectamine LTX complexes. Growth medium was 
removed from the cells and replaced with 0.5 ml of complete growth medium. 100 µl of 
the DNA-Lipofectamine LTX complexes were added dropwise directly to each well 
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containing cells and mixed gently by rocking the plate back and forth. Transfected cells 
were then incubated in normal incubating conditions. Two wells were transfected with 
pCMV6-AC-HA-MIIP plasmid and two wells with pCMV-AC-HA empty plasmid. 
To generate cell lines stably expressing MIIP, transfected DU145 cells were selected 
in the presence of 400 µg/ml geneticin (G418; Gibco
®
, Life Technologies, Carlsbad, 
CA) for 3 weeks and after that maintained in 200 µg/ml of G418. Transfected DU145 
cells were seeded sparsely on 10 ml petri dishes and individual colonies were ring-
cloned into 96-well plates to achieve populations originating from a single cell. 
Colonies were further grown in normal cell culturing conditions to gain sufficient 
amount of cells for the functional tests. 
siRNA transfections for LAPC-4 cells were done using INTERFERin (Polyplus-
transfection SA; Illkirch, France) and its reverse transfection protocol. In short, for each 
well, 30 pmol (in the optimizing phase also 6 pmols) of siRNA duplexes were diluted 
into 100 µl of Opti-MEM. 3 µl of INTERFERin was added to the diluted siRNAs and 
the solution was mixed by pipetting up and down. The mixture was incubated for 15 
minutes at room temperature to form transfection complexes. For proliferation assays, 
LAPC-4 cells were trypsinazed and plated 100 000 cells per well on 24-well plates. 100 
µl of the siRNA solution was pipetted on each well and mixed gently by moving the 
plate in a figure of 8. After transfection, cells were incubated at 37ºC in normal cell 
culturing conditions. 8 wells were transfected with each siRNA; MIIP siRNA1, MIIP 
siRNA2 and Qiagen All Stars negative control. Proliferation assays were started the day 
after transfection (day 0). 
Transfections for migration analysis were done in a similar manner, except LAPC-4 
cells were plated 300 000 cells per well and 350 000 cells per well on 24-well plates. 3 
days later scratches was drawn across (from 11 o’clock to 5 o’clock) the confluent cell 
layer on the bottom of the wells with a 10 µl pipette tip. 100 µl of the incubated siRNA 
solution was pipetted dropwise on each well. 4 parallel samples (one of 300 000 cells 
per well and three of 350 cells per well) was used for each siRNA; MIIP siRNA1, MIIP 
siRNA2, MIIP siRNA3 and control siRNA. First images were taken the day of 
transfection (day 0). 
 
8.4 Sequencing 
Genomic DNA from cell line and xenograft samples was also amplified with Dynazyme 
II as with plasmid DNA, using 400 ng of DNA for cell lines and 200 ng of DNA for 
xenografts. Cell line and xenograft PCR reactions were also purified with QIAQuick 
PCR purification kit (Qiagen, Venlo, Netherlands) according to manufacturer’s protocol 
prior to sequencing reactions. For full length transcript sequencing, complementary 
cDNA from cell lines was amplified with Phusion DNA Polymerase (Finnzymes, 
Espoo, Finland) and purified with QIAQuick PCR purification kit (Qiagen, Venlo, 
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Netherlands) prior to sequencing with the protocol described in tables 2 and 3. Primer 
sequences can be found from Table 4. 
 
Table 2: Phusion PCR Program outline 
 
Phusion PCR Program 
Cycle step Temperature Time Number of cycles 
Initial denaturation 98ºC 3 min 1 
Denaturation 98 ºC 10s  
40 Annealing 56,3/57 ºC 20s 
Extension 72 ºC 30s 
Final extension 72 ºC 10 min 1 
Cooling 4 ºC hold 1 
 
Table 3: Phusion PCR components and pipetting order 
 
Phusion PCR components and pipetting order 
Component µl/20 µl reaction 
H2O 11.72 
5x Phusion GC Buffer 4 
dNTPs 0.4 
DMSO 0.6 
MgCl2 0.08 
Phusion DNA polymerase 0.2 
forward-primer 10 µM 1 
reverse-primer 10 µM 1 
template DNA 1  
 
Sequencing was performed using the Big-Dye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems, Foster City, CA) and the ABI PRISM 3100 sequencer 
(Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. 
Each sequencing reaction included 20 ng of DNA, 5 pmol of primers, 1.5 µl of 5x 
sequencing buffer and 1.0 µl of BigDye Terminaton ready Reaction mix (Applied 
Biosystems, Foster City, CA). The volume of the reactions was adjusted to 10 µl with 
sterile water. Sequences for the primers used can be seen in Table 4. The sequencing 
reactions were denatured at 96 °C for 1 minute, followed by 30 cycles of 10 s at 96 °C, 
10 s at 50 °C and 4 min at 60 °C. 
Amplified DNA was precipitated by adding 26 µl of a mixture containing one part 
of 3 M sodium acetate and 25 parts of 96% ethanol and incubating for 15 minutes at 
room temperature. DNA was pelleted by centrifugation at 2000 g for 45 minutes and the 
supernatants were discarded. Pellets were washed with 125 µl of 70 % ethanol and 
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DNA was re-pelleted by centrifugation at 2000 g for 15 minutes. Supernatants were 
again discarded and the DNA pellet was suspended into 12.5 µl of Hi-Di
TM
 formamide 
(Applied Biosystems, Foster City, CA). Suspensions were denatured by incubating the 
samples at 95 for 3 minutes and after that cooled on ice. Sequences were analyzed with 
DNAStar Software (DNASTAR Inc., Madison, WI, USA). 
 
8.5 Determination of MIIP mRNA levels 
8.5.1 RNA isolation 
Total RNA from cultured cells was isolated using TRIZOL (Invitrogen Life 
Technologies, Carlsbad, CA) reagent according to manufacturer’s protocol. Shortly, 
cells were lysed by adding 1 ml of TRIZOL reagent per 10 cm
2
 (200 µl per 24-well) 
directly to the culture dish and the cell lysate was passed through the pipette several 
times. Lysate was pipetted to a plastic tube and stored in the freezer at -70ºC if the 
isolation was not continued right away. 
Samples were then incubated at room temperature for 5 minutes. 0.2 ml of 
chloroform was added per 1 ml of TRIZOL reagent (40 µl for one 24-well), tubes were 
capped, shaked vigorously by hands for 15 seconds and incubated for 3 minutes. 
Samples were centrifuged at 12000 x g for  15 minutes at 2-8°C for phase separation. 
The colourless upper aqueous phase containing the RNA was transferred to a fresh tube 
and the rest was discarded. RNA was precipitated from the aqueous phase by adding 0.5 
ml of isopropyl alcohol per 1 ml of TRIZOL reagent (100 µl for one 24-well). Samples 
were incubated at room temperature for 10 minutes and centrifuged at 2-8°C at 12000 x 
g for 10 minutes. The supernatant was discarded and the gel-like pellet formed in the 
bottom of the tube was washed once with 75 % ethanol using at least 1 ml of ethanol 
per 1 ml of TRIZOL reagent used in the beginning. Samples were mixed by vortexing 
and centrifuged at 7500 x g for 5 minutes at 2-8°C. The ethanol was removed and the 
RNA pellet was air dried. The dried RNA pellet was dissolved in RNase-free water by 
passing the solution a few times through the pipette tip. 
8.5.2 Reverse transcription and quantitative RT-PCR 
In order to carry out complementary DNA (cDNA) reverse transcription, concentrations 
of total RNA were determined using NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA). 
1-5 micrograms of total RNA from cell samples was reverse transcribed to cDNA with 
AMV-reverse transcriptase (Finnzymes, Espoo, Finland) according to the enzyme 
manufacturer's protocol using random hexamer primers. 
Quantitative real-time PCR (Q-RT-PCR) was done with the LightCycler equipment 
(Roche Diagnostics, Mannheim, Germany) using FastStart DNA Master SYBR Green I 
Kit (Roche Diagnostics, Mannheim, Germany) for xenograft samples. For the rest of the 
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samples Q-RT-PCR was done with CFX96 real-time PCR detection system (Bio-Rad 
Laboratories Inc., Hercules, CA) using TaqMan Gene Expression assay (Applied 
Biosystems, Foster City, CA) for MIIP expressions and Maxima™ SYBR Green 
(Fermentas Inc., Burlington, Ontario, Canada) for TBP expressions. The expression 
levels of MIIP were normalized by the expression level of the housekeeping gene for 
TATA box binding protein (TBP). The sequences for the PCR-primers were designed 
with Primer3-program (http://bioinfo.ut.ee/primer3-0.4.0/primer3/input.htm) and can be 
seen in Table 4. TaqMan probe Hs00976263_m1 (Applied Biosystems, Foster City, 
CA) was used for detection of MIIP. The specificity of the reactions was confirmed 
with 1% agarose gel electrophoresis in addition to the melting curve analysis. Standard 
curve was done using LNCaP + universal prostate cDNA (stock 14.6-10) by using 5-
fold dilution series. 
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Table 4: Primer sequences. 
 
Sequencing primers for plasmids 
 Primer sequence 5’-3’ 
forward vector primer T7 TAATACGACTCACTATAGGG 
reverse vector primer XL39 ATTAGGACAAGGCTGGTGGG 
forward MIIP AAAGAGCTTTGACGCCTCTG 
reverse MIIP GTCAGTCCTCAGGGCTTCTG 
SNP sequencing primers for cell lines and xenografts 
 Primer sequence 5’-3’ 
forward MIIP AAGAGGCTCCTGGGAGATAC 
reverse MIIP GAGGATGGCACGGTCAGA 
PCR primers for Dynazyme PCR for plasmids 
 Primer sequence 5’-3’ 
forward MIIP AAAGAGCTTTGACGCCTCTG 
reverse MIIP GTCAGTCCTCAGGGCTTCTG 
PCR primers for Dynazyme PCR for cell lines and xenografts 
 Primer sequence 5’-3’ 
forward MIIP AAAGAGCTTTGACGCCTCTG 
reverse MIIP GTCAGTCCTCAGGGCTTCTG 
RT-qPCR primers 
 Primer sequence 5’-3’ 
forward MIIP AAAGAGCTTTGACGCCTCTG 
reverse MIIP GTCAGTCCTCAGGGCTTCTG 
forward TBP GAATATAATCCCAAGCGGTTTG 
reverse TBP ACTTCACATCACAGCTCCCC 
Phusion PCR and transcript sequencing primers 
forward 1
st
 MIIP TCACCTGACCAATCAAGACG 
reverse 1
st
 MIIP AGGCGCCAGCTCCTCTTA 
forward 2
nd
 MIIP CGAGACCCCACTCAGCAC 
reverse 2
nd
 MIIP TGTCAGAGGCGTCAAAGCTC 
forward 3
rd
 MIIP TGCGTGTACTGTTACCGTGTC 
reverse 3
rd
 MIIP CAGACAAGCTTGGGTCCAC 
8.6 Determination of MIIP protein levels 
8.6.1 Protein isolation 
25 ml cell culture flasks were placed on ice and the cells were washed three times 
with 10 ml of ice cold phosphate buffered saline (PBS). Cells were then collected into 
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1.5 ml of PBS with rubber policeman and the tubes were centrifuged gently. Any excess 
PBS was removed from the tubes and the tubes were stored at -70 ºC. 
Nuclear and cytoplasmic proteins were isolated using modified Dignam’s method 
(Dignam et al. 1983). The samples were melted on ice and possible excess PBS was 
removed. The volume of the cell pellet was estimated and it was suspended to three 
times the volume of the pellet of hypotonic buffer (for detailed composition, see 
Appendix 1). The solution was homogenized by pipetting back and forth for 10 seconds 
and incubated on ice for 10 minutes. The samples were centrifuged at 3300 x g at 4 ºC 
for 15 minutes. The supernatant containing cytoplasmic proteins was carefully collected 
and stored at -80 ºC.  
The pellet containing nuclear proteins was diluted to low-salt buffer (for detailed 
composition, see Appendix 1) to a volume half of that of the hypotonic buffer used for 
the same sample. The solution was mixed by pipetting back and forth a few times 
before adding high-salt buffer (for detailed composition, see Appendix 1) in a dropwise 
manner. The volume of the high-salt buffer used was half the volume of low-salt buffer 
used for the same sample. The samples were incubated on ice for 30 minutes and mixed 
gently during the incubation. After incubation, the samples were centrifuged at 2500 x g 
for 30 minutes at 4 ºC. Supernatant was collected and stored at-80 ºC. 
Protein samples were diluted 1:100 with water for concentration measurements. The 
standard curve was prepared from bovine serum albumin (BSA) with concentrations of 
8, 26, 44, 62 and 80 µg/ml. Protein concentrations were measured with Bio-Rad protein 
assay reagent (Bio-Rad Laboratories Inc., Hercules, CA). 40µl of Bio-Rad reagent was 
added to 160µl of standard or diluted sample. The samples were incubated at room 
temperature for 15 minutes and after that absorbances were measured at 595 nm with 
Multiskan GO Microplate Spectrophotometer (Thermo Scientific, Thermo Fisher 
Scientific, Inc., Waltham, USA). 
8.6.2 SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
carried out in a 10% separating gel and a stacker gel (for details, see Appendix 2). 
Protein samples were diluted with water to two different concentrations: 1 µg/µl and 
0.65 µg/µl to a total volume of 10 µl. 10 µl of a mixture containing 9/10 parts of 3 x 
SDS reaction sample buffer (Bio-Rad Laboratories Inc., Hercules, CA) and 1/10 parts of 
1.25 M dithiothreitol (DTT) was added to samples, mixed and the samples were then 
denaturated at 97ºC for three minutes. Samples were then loaded in the wells of the gel. 
Kaleidoscope Prestained Standard (Bio-Rad Laboratories Inc., Hercules, CA) was used 
as a marker. The samples were run with Bio-Rad Mini-PROTEAN
®
 3 Cell, 67S/09185 
(Bio-Rad Laboratories Inc., Hercules, CA) with 100 V to the interface of the gels (about 
15 minutes) and after that the voltage was raised to 200 V. Samples were run until the 
dye of the SDS sample buffer reached the bottom of the gel (about one hour). 
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8.6.3 Western blotting 
Western blotting was done with Bio-Rad Trans-Blot
® 
SD Cell, 221BR 18151 (Bio-
Rad Laboratories Inc., Hercules, CA). Immobilon-P PVDF membrane (Millipore, 
Billerica, MA, USA) was cut to appropriate size and prepared for blotting by soaking it 
in methanol for 15 seconds, in water for 5 seconds and transferring it then into the 
blotting buffer (see Appendix 2). First, three pieces of chromatography paper 
(Whatman, Brentford, UK) were soaked in the blotting buffer and placed on the blotting 
cell. Then, PVDF membrane was placed on top of the papers and the SDS-PAGE gel on 
top of the membrane. At last, three pieces of chromatography paper soaked in the 
blotting buffer were laid on top. The blotting was carried out at 20 V for one hour. 
The PVDF membrane was carefully moved to mixture made of 2.5 grams of 
powdered milk and 50 ml of PBS and blocked overnight at 4ºC. The primary 
monoclonal antibody HA.11 Clone 16B12 (Covance Inc., Delaware, USA) was diluted 
1:1000 in a 1% BSA, PBS-0.1%Tween-20 mixture. After blocking, the membrane was 
placed to the primary antibody solution and incubated for two hours at room 
temperature. The membrane was washed five times for 5 minutes with PBS-Tween20. 
The secondary polyclonal antibody, rabbit anti-mouse immunoglobulins (Dako, 
Glostrup, Denmark) was diluted 1:1000 in a 1% BSA, PBS-0.1%Tween-20 mixture. 
The membrane was placed to the secondary antibody solution and incubated for one 
hour at room temperature. The membrane was then washed again two times for 10 
minutes and once for 20 minutes with PBS-Tween20.  
The detection was done with Western Blotting Luminol Reagent, cat# sc-2048 
(Santa Cruz Biotechnology, Santa Cruz, CA) for one minute. The films (Kodak BioMax 
MR Film, Sigma-Aldrich Co., Missouri, USA) were exposed for 15 seconds. 
8.7 Proliferation assays 
Proliferation of transfected cells was measured with alamarBlue and image analysis 
methods. For proliferation assays, stable DU145 clones and parental DU145 cells were 
plated 5000 cells per well on 24-well plates. Four parallel samples were used in each 
experiment. Proliferation assays were initiated the next day from plating (day 0). 
LAPC-4 cells were plated 100 00 cells per well and transfected as previously 
described for proliferation assays. Four parallel samples were used in each experiment. 
8.7.1 AlamarBlue 
The amount of cells in the beginning of the experiment and in the end of the 
experiment was analyzed using alamarBlue reagent (Invitrogen Life Technologies, 
Carlsbad, CA). 10% alamarBlue reagent was added to every well and the plates were 
incubated at 37ºC and 5%  CO2 for 3 hours for DU145 cells and 2 hours for LAPC-4 
cells. After incubation, 100µl of alamarBlue containing medium from each well was 
pipetted to a 96-well plate. The fluorescence was measured with ELISA plate reader, 
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(Wallac 1420 Victor, PerkinElmer, Fremont, CA). Medium with 10% added alamarBlue 
reagent without cells was used as a control. For relative growth analysis, the 
luminometric values of the cells in each well at the end of the experiment were divided 
by the mean values at the beginning of the experiment. 
8.7.2 Imaging and image analysis 
25 images from each well were taken at regular intervals using motorized, inverted 
fluorescence imaging microscope system (Märzhäuser micro-positioning systems, 
Germany). The amount of cells in each well was analyzed by calculating the area of the 
images covered by living cells using freely available ImageJ image analysis software 
(http://imagej.nih.gov/ij/). Values were normalized with the area covered by cells in 
each well at the first day of imaging (day 0). 
8.8 Migration assays 
For LAPC-4 cells, scratches were drawn to the cell layer in the bottom of the wells 
prior to siRNA transfections as previously described. For stable DU145 clones and 
parental DU145 cells, 100 000 cells were plated on each 24-well plate well. The next 
day, scratches was drawn across (from 11 o’clock to 5 o’clock) the confluent cell layer 
on the bottom of the wells with a 10 µl pipette tip in the same manner as for LAPC-4 
cell, growth medium was exchanged and cells were imaged. 
25 images from each well were taken at regular intervals using motorized, inverted 
fluorescence imaging microscope system (Märzhäuser micro-positioning systems, 
Germany). The size of the scratch was analyzed by manually drawing the edges of the 
scratch and calculating the surface area of it with ImageJ image analysis software. 
Values of each well were compared to the area of the scratch in that well at the first day 
of imaging (day 0). 
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9. RESULTS  
9.1 Sequencing 
A segment of MIIP gene containing SNP rs2295283 previously shown to affect the risk 
of breast cancer was sequenced from seven prostate cancer cell line and 17 prostate 
cancer xenograft genomic DNA samples. Cell line copy numbers and most xenograft 
copy numbers (23.1, 35, 49, 58, 69, 70, 73, 77, 86.2, 93, 96, 105 and 115) were obtained 
from Saramäki et al. (2006) data and the rest of the xenograft copy numbers from 
Kivinen, Saramäki et al. (unpublished). The results are shown in Table 5. 
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Table 5: Copy numbers and single nucleotide polymorphism forms of MIIP in prostate 
              cancer cell lines and LuCaP xenografts 
 
Cell line/ 
Xenograftt 
Copy 
nro 
SNP 
DU145 1 A- 
VCaP 2 GG 
PC-3 2 AA 
LNCaP 2 AG 
DuCaP 2 GG 
22Rv1 2 GG 
LAPC-4 3 AG/n/a 
LuCaP 23.1 2 GG 
LuCaP 23.1 AI 1 n/a 
LuCaP 23.8 n/a GG 
LuCaP 23.12 1 G- 
LuCaP 35 2 n/a 
LuCaP 35 AI 1 G- 
LuCaP 41 1 n/a 
LuCaP 49 1 A- 
LuCaP 58 2 GG 
LuCaP 69 1 G- 
LuCaP 70 2 GG 
LuCaP 73 2 AG 
LuCaP 77 2 GG 
LuCaP 78 2 AG 
LuCaP 81 2 n/a 
LuCaP 86.2 2 AA 
LuCaP 92.1 n/a GG 
LuCaP 93 2 AA 
LuCaP 96 1 G- 
LuCaP 96AI 1 n/a 
LuCaP 105 2 AG 
LuCaP 115 1 G- 
 
AA means both alleles contain A, AG means one allele contains A and the other G and 
GG means both alleles contain G. If information of the copy number or SNP status was 
not available, it is marked as n/a.  
Of the 24 cell line and xenograft samples sequenced, 58% carried GG (or G-), 21% 
AA (or A-) and 21% AG form of the functional SNP in MIIP in their genome. Genomic 
DNA and copy number information was not available for some samples (indicated n/a).  
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The full-length transcript of MIIP was also sequenced in three parts from 7 cell line 
cDNA samples to identify possible mutations. Mutations were not detected in the 
samples screened.  
9.2 Expression levels of MIIP 
9.2.1 MIIP mRNA levels 
Relative expression of MIIP in prostate cancer cell lines and xenografts was measured 
with quantitative RT-PCR to evaluate the connection of the level of expression of MIIP 
with SNP results and to determine which cell lines to use for functional experiments. 
The expressions are plotted in Figures 5 and 6. 
 
 
Figure 5: The relative expression of MIIP (MIIP/TBP) in different prostate cancer cell 
lines.  
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Figure 6: The relative expression of MIIP (MIIP/TBP) in prostate cancer LuCaP 
xenografts 
 
The lowest expression of MIIP in cell lines was found in 22Rv1 and PC3 and in 
LuCaP xenografts in 96AI, 23.1, 78 and 69.  
LAPC-4 cell line with the highest expression of MIIP was chosen for experiments 
with small interfering RNAs (siRNAs) to properly see the effects of gene silencing. 
LAPC-4 cells were transfected with four different siRNAs targeting MIIP (indicated 
with numbers 1,2,3 and 4), a pool of aforementioned containing equal amount of each 
siRNA and a control siRNA in two different concentrations to determine the optimal 
transfection conditions. Relative expression of MIIP was measured from the samples 
with quantitative RT-PCR and the results can be seen in Figure 7. 
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Figure 7: Relative expression of MIIP (MIIP/TBP) in LAPC-4 after different siRNA 
transfections. 
 
MIIP was found to be most efficiently silenced with 50 nM siRNAs 1 and 3. In 
those samples, the expression of MIIP was less than one third of that of the control. The 
difference in expression between siRNAs 2 and 3 was so small, that siRNA 1 and 2 
were used for proliferation assays. In the migration assay, also siRNA 3 was included. 
Interestingly, DU145, a cell line derived from PC brain metastasis, was found to 
express MIIP in relatively low levels, and to carry only one copy of MIIP and the more 
risk prone A-genotype of the SNP rs2295283. For these reasons, and due to fast growth 
of cells, DU145 cells were chosen for MIIP overexpression studies. DU145 cells were 
transfected with a pCMV6-AC-HA plasmid containing MIIP and an empty pCMV6-
AC-HA control plasmid. Stable clones were created and their relative expression of 
MIIP was measured. Results are shown in Figure 8. 
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Figure 8: Relative expression of MIIP (MIIP/TBP) in stable DU145 clones. 
 
Over eightfold expression was seen in clones MIIP A1 and MIIP A6 transfected 
with the plasmid containing MIIP when compared to controls empty A2 and empty A4 
with the lowest expression of MIIP (clones indicated MIIP A1, MIIP A6, empty A2 and 
empty A4 according to the wells they were first ringcloned to in 96-wellplates).  
 
9.2.2 MIIP protein level 
Due to technical difficulties, MIIP protein level could not be measured. Protein 
concentrations after isolation were low or could not be measured for most nuclear 
protein components. 
9.3 Proliferation assays 
 
Relative growth of transfected cells was assessed with image analysis method and with 
alamarBlue method as described in sections 8.7.1 and 8.7.2. 
Relative growth of siRNA transfected LAPC-4 cells measured with both methods 
are shown in Figures 10 and 11. 
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Figure 10: Relative growth of siRNA transfected LAPC-4 cells obtained by image 
                  analysis 
 
 
Figure 11: Relative growth of siRNA transfected LAPC-4 obtained with alamarBlue 
 
Transfections with MIIP siRNA 1 caused the cells to eventually detach from the 
bottom of the wells, so no growth was observed. In Figure 10, it seems that some 
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growth was seen with MIIP siRNA 1. However, the misguided information is due to 
floating cells that the image analysis software incorrectly interpreted as growing cells.  
Image analysis results show, that the growth of the cells transfected with MIIP 
siRNA 2 was faster than with the cells transfected with control siRNA (p=0.03<0.05, 
Mann-Whitney U-test). On the contrary, alamarBlue results show that the metabolism in 
MIIP siRNA 2 transfected cells is lower than in the control (p=0.03<0.05, Mann-
Whitney U-test) It should be noted that transfections with the control siRNA caused 
changes in the phenotype of the cells. LAPC-4 cells grow clustered together also in 
normal conditions but the transfection with control siRNA caused the cell clusters to be 
more round and distinct from each other.  
Relative growth of stable, MIIP overexpressing DU145 clones was also assessed 
with both methods and the results are seen in Figures 12 and 13.  
 
 
Figure 12: Relative growth of stable DU145 clones obtained by image analysis. 
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Figure 13: Relative growth of stable DU145 clones obtained with alamarBlue. 
 
With image analysis, it was seen that the growth was only a little faster with the 
clones with the higher expression of MIIP (MIIP A1 and MIIP A6) than with the empty 
controls (empty A2 and empty A4) (p=0.19>0.05, Mann-Whitney U-test). The growth 
of all transfected clones (MIIP and empty control) was significantly faster than with 
parental DU145 (p=0.0004<0.05, Mann-Whitney U-test). AlamarBlue showed that the 
metabolic activity was significantly higher in controls empty A2 and empty A4 than in 
MIIP A1 and MIIP A6 clones with higher expression of MIIP (p=0,0002<0,05, Mann-
Whitney U-test). The lowest metabolic activity in the transfected clones was observed 
in MIIP A6 which had the highest expression of MIIP. 
 
9.4 Migration assays 
The effect of MIIP expression on cell migration was studied with scratch assay. Figure 
14 representing relative scratch size in siRNA transfected LAPC-4 shows that 
significant difference was not seen between migration in cells transfected with MIIP 
siRNAs and cells transfected with control siRNA (p=0,33>0,05, Mann-Whitney U-test). 
Transfection with MIIP siRNA 1 did not cause the cells to completely detach from the 
bottom of the wells as in the proliferation assay, but it prevented the cells from 
migrating. Transfection in general with all siRNAs inhibited migration which was seen 
when compared to parental LAPC-4 (data not shown). 
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Figure 14: Relative scratch size in siRNA transfected LAPC-4 cells. 
 
Results of the effect of MIIP overexpression on cell migration in stable DU145 
clones are shown in Figure 15.  
 
 
Figure 15: Relative scratch size in stable DU145 clones and in parental DU145. 
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The migration of parental DU145 was very significantly faster than that of 
transfected clones (p=0,000075<0,05, Mann-Whitney U-test) and clones MIIP A1 and 
MIIP A6 migrated significantly faster than clones empty A2 and empty A4 
(p=0,000018<0,05, Mann-Whitney U-test). 
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10. DISCUSSION 
In this study, we examined the effect of MIIP on prostate cancer cell proliferation and 
migration by overexpressing and silencing MIIP in two prostate cancer cell lines. In 
addition, the gene was screened for mutations and SNP rs2295283 previously proven to 
affect the risk of breast cancer. Previous studies have shown overexpression of MIIP to 
inhibit proliferation and migration in glioma cell lines (Song et al. 2003). This gene and 
its effects in prostate cancer have not been previously studied. Due to its significance in 
other cancer types, mechanisms of action of the protein and the location of the gene in a 
commonly deleted area, the effect of MIIP in prostate cancer is a topic worth studying.  
 
10.1 Methodological aspects 
MIIP protein level could not be discovered. One possible reason for this could lie in the 
used antibody. The antibody has previously been used in another research group with no 
problems. However, the received aliquot had been stored for some time before using it 
again in this assay. Even though it had been stored according to manufacturer’s 
instructions, it is possible that the storage time could have reduced the efficacy of the 
antibody. Since the antibody used was against the human influenza hemagglutinin (HA) 
tag of the protein, it is also possible that for some reason the expression of the tag was 
disrupted and caused the antibody not to recognize the protein. 
Image analysis was done using ImageJ software. Measured proliferation was based 
on the area of the cells covering the well. Since the area of the wells is relatively small, 
any air bubbles left in the surface of the growth media during plating or media 
exchange, might affect the amount of cells seen in a specific image.  
ImageJ program calculated the area covered by cells based on contrast differences 
between areas where cells were growing and the background. Since cells were grown in 
a humidified incubator, condensing water on the lids of the plates made lightning 
adjustments of the microscope very difficult as the amount of condensed water was 
different on each well and at each timepoint. Too much lightning caused ImageJ to 
interpret also areas with cells as background, especially with DU145 cells which seem 
very transparent in the bottom of the culture vessel. Contrast could be enhanced with 
ImageJ, but it probably still caused some errors in the calculated values. Also floating 
cells detached from the bottom were incorrectly interpreted as growing cells by the 
software and might have had an effect on the achieved results.  
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Scratch area was measured with ImageJ by manually defining the edges of the 
scratch. Although the work was done with utmost attention in the accuracy, human 
errors are still possible. Due to these numerous difficulties, results from image analysis 
methods in both assays are very unreliable. Results from alamarBlue method should be 
considered more trustworthy. 
Transfections with all siRNAs reduced proliferation and migration when compared 
to parental LAPC-4 cells. Transfections with all siRNAs also caused changes in the 
phenotype of the cells and transfection with MIIP siRNA1 caused the cells to detach 
from the bottom of the wells in the proliferation assay. Transfection in general is a 
procedure that can disrupt the highly orchestrated balance of cellular functions so these 
alterations could be due to that. It is also possible that the siRNAs were not completely 
specific to MIIP and interfered also the expression of other genes. In migration assays, 
transfection efficiency also suffers from the fact that cell density is high. Maybe by 
optimizing the transfection conditions even further and possibly using a lower 
concentration of siRNAs, better results could have been achieved. Therefore, 
conclusions about the connection of silencing MIIP and cell migration cannot be drawn 
until the assays have been replicated with different conditions and possibly different 
siRNAs and the results confirmed. 
10.2 Sequencing 
The entire MIIP gene was sequenced from prostate cancer cell lines and xenografts for 
mutations and SNPs. Mutations have not been found in previous studies in other cancers 
and they were not distinguished in this study either (Song et al. 2005, Wang et al. 2010). 
However, as stated earlier, this does not rule out MIIP being a tumor suppressor. 
Mutation is not the only mechanisms that can inactivate tumor suppressors and since the 
overall mutation rate in prostate cancer is relatively low (~1 per MB) compared to other 
cancers, these alternative inactivating mechanisms may play even bigger role in prostate 
cancer than in other cancers (Barbieri and Tomlings 2014). One possible way could be 
alternative splicing, which has been seen in gliomas and was not studied in this thesis 
(Song et al. 2005). 
If SNP rs2295283 would have a drastic effect on prostate cancer risk, it could be 
thought that the more risk prone allele A would be more common among cancer cell 
lines and xenografts. However, most of the samples carried the protective G allele in 
their genotype either as homozygous or heterozygous. This would implicate that SNP 
rs2295283 has no considerable effect on prostate cancer risk. In addition, clear 
correlation between SNP rs2295283 variant and expression of MIIP was not seen, 
supporting this conclusion. 
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10.3 Proliferation and migration assays 
It could be hypothesized that when a tumor suppressor gene is silenced, the growth of 
these cells is accelerated. And in turn, when the expression of a tumor suppressor is 
increased, growth is hindered. However, in reality the situation is not necessarily that 
simple. Since the regulatory mechanisms of cancer cells are already impaired, silencing 
yet another protection mechanism could function as the final trigger to induce apoptosis. 
Then again, cancer cells develop mechanisms to overcome growth obstacles rather 
readily (Hanahan and Weinberg 2000). Thus, overexpressing a single growth 
suppressing gene may not have that drastic effect on growth, when growth inhibitory 
signals are cancelled out with new or excess growth promoting ones. 
Transfections with all siRNAs inhibited LAPC-4 cell migration compared to 
parental cells and significant differences in migration between cells transfected with 
MIIP siRNAs or with control siRNA were not seen. Image analysis showed that the 
growth of the cells transfected with MIIP siRNA 2 was faster than with the cells 
transfected with control siRNA but as stated earlier, results are not very reliable. On the 
contrary, alamarBlue results show that the metabolism in MIIP siRNA transfected cells 
is lower than in the control.  
In the proliferation assays, image analysis method revealed that stable MIIP 
overexpressing DU145 cells proliferated slightly faster than cells transfected with the 
control vector and significant differences were not observed. All transfected cells also 
proliferated faster than parental DU145 cells. However, results of the image analysis 
method cannot be fully trusted. AlamarBlue assay showed the metabolic activity of cells 
transfected with MIIP to be significantly lower than in cells transfected with control 
vector. Metabolic activity of parental DU145 cells was found to be lower than that of 
transfected ones. Transfection in general seemed to decelerate migration since migration 
of all transfected clones was significantly slower than that of parental DU145. DU145 
cells overexpressing MIIP also migrated significantly faster that cells transfected with 
control vector.  
In both cell lines and transfection methods, similar contradiction was seen in the 
proliferation results of image analysis method and alamarBlue method. It is possible 
that even though overexpression of MIIP did not slow DU145 cell growth, it caused 
changes in cell metabolic activity. The metabolic activity of the transfected clones was 
seen to be the lowest with the DU145 clone expressing highest levels of MIIP, which 
supports this possibility. However, it is more likely that this contradiction is caused by 
some systematic error in performing the assays or by the problems with image analysis. 
Due to numerous technical difficulties in the image analysis method, results of 
alamarBlue should be considered more reliable and results of image analysis method in 
both assays should not be fully trusted. Differences between samples transfected with 
siRNAs were so minor, even though considered statistically significant, and number of 
samples was so small that conclusions should not be drawn, especially when taking into 
notice other issues related to the siRNA transfections described earlier. 
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A simple explanation for the results could be that MIIP does not have a direct effect 
on cell proliferation and migration and for that reason overexpression or silencing of the 
gene does not have an apparent effect on the behaviour of the cells on such short time 
scale. The observed changes in cell growth and migration can also be due to other 
factors, such as harmful effects of the transfection process, transfection efficiency or 
other extrinsic factors. Also, the effect of MIIP on proliferation and migration in 
prostate cancer cells might be dependent on some other, still unknown factor or factors 
that were not present in sufficient quantities in the studied cells. 
It is also possible, that other prostate cancer cell lines would behave differently in 
these assays. They all have their distinct properties and only LAPC-4 and DU145 cells 
were tested in this study. It should be noted, that stable transfections with pCMV-AC-
HA-MIIP and the control vector was attempted also for LNCaP cell line (data not 
shown). Despite optimizing the transfection protocol several times and using different 
transfection reagents, stable clones overexpressing MIIP eventually died. It is possible 
that overexpression of MIIP had a more notable inhibitory effect on cell growth in 
LNCaP cells and cell death was at least partly due to that. Then again, also cells 
transfected with control vector eventually died, although later than those overexpressing 
MIIP. Thus, the reason for the failure in maintaining transfected cells was more likely 
that LNCaP cells were more sensitive to transfection conditions and optimal conditions 
were not found in spite of persistent attempts. 
It should also be remembered that prostate cancer cell lines and clinical prostate 
cancer are very different things. Clinical prostate cancer is genetically remarkably 
heterogenic and clinically variable (Barbieri and Tomlings 2014). Many changes occur 
in cancer cells during progression of the disease and cancer cell lines represent quite 
advanced stages of cancer. The behaviour of cells also changes when they are grown in 
laboratory conditions and go through multiple passaging series. However, they 
represent an easy and in some cases also only possibility to model effects of different 
genetic events on behaviour of cells. It is still possible that MIIP could have a more 
profound effect in earlier stages of prostate cancer. 
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11. CONCLUSIONS 
In conclusion, the observed effect of MIIP in prostate cancer cells was small and 
inconsistent. It seems unlikely that MIIP plays a significant role in all or most prostate 
cancer cases. However, prostate cancer is very heterogeneous and there are numerous 
different kinds of prostate cancers. It is thus possible, that MIIP has an important effect 
in genesis and/or progression of some of the subtypes, even though tests with the 
studied cell lines and xenografts did not reveal significant effects. More experiments are 
needed to fully uncover the effect of MIIP in prostate cancer cells. 
 
 
   52 
 
REFERENCES 
Abate-Shen C. & Shen M.M. (2000). Molecular genetics of prostate cancer. Genes Dev. 
14, pp. 2410−2434. 
American cancer society. [WWW]. [accessed on 25.04.2011]. Available at: 
http://www.cancer.org/. 
Abrahamsson P.A. (2010). Potential benefits of intermittent androgen suppression 
therapy in the treatment of prostate cancer: a systematic review of the literature. Eur 
Urol. 57, 1, pp. 49−59. 
Attard G., Reid A.H., Yap T.A., Raynaud F., Dowsett M., Settatree S., Barrett M., 
Parker C., Martins V., Folkerd E., Clark J., Cooper C.S., Kaye S.B., Dearnaley D., Lee 
G., de Bono J.S. (2008). Phase I clinical trial of a selective inhibitor of CYP17, 
abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains 
hormone driven. J Clin Oncol. 26, 28, pp. 4563−71. 
Attardi B.J., Burgenson J., Hild S.A., Reel J.R. (2004). Steroid hormonal regulation of 
growth, prostate specific antigen secretion, and transcription mediated by the mutated 
androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol Cell Endocrinol. 
222, 1-2, pp. 121−32. 
Babaian R.J., Donnelly B., Bahn D., Baust J.G., Dineen M., Ellis D., Katz A., Pisters L., 
Rukstalis D., Shinohara K., Thrasher J.B. (2008). Best practice statement on 
cryosurgery for the treatment of localized prostate cancer. J Urol. 180, 5, pp. 
1993−2004. 
Barbieri C.E., Tomlins S.A. (2014). The prostate cancer genome: perspectives and 
potential. Urol Oncol. 32, 1, pp. 15−22. 
Best C.J., Gillespie J.W., Yi Y., Chandramouli G.V., Perlmutter M.A., Gathright Y., 
Erickson H.S., Georgevich L., Tangrea M.A., Duray P.H., González S., Velasco A., 
Linehan W.M., Matusik R.J., Price D.K., Figg W.D., Emmert-Buck M.R., Chuaqui R.F. 
(2005). Molecular alterations in primary prostate cancer after androgen ablation therapy. 
Clin Cancer Res. 11, 19 pp. 6823−34. 
Bethel C.R., Faith D., Li X., Guan B., Hicks J.L., Lan F., Jenkins R.B., Bieberich C.J., 
De Marzo A.M. (2006). Decreased NKX3.1 protein expression in focal prostatic 
atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with 
gleason score and chromosome 8p deletion. Cancer Res. 66, 22, pp. 10683−90. 
Bieberich C.J., Fujita K., He W.W., Jay G. (1996). Prostate-specific and androgen-
dependent expression of a novel homeobox gene. J Biol Chem. 271, 50, pp. 31779−82. 
Bill-Axelson A., Holmberg L., Ruutu M., Häggman M., Andersson S.O., Bratell S., 
Spångberg A., Busch C., Nordling S., Garmo H., Palmgren J., Adami H.O., Norlén B.J., 
   53 
 
Johansson J.E. (2005) Scandinavian Prostate Cancer Group Study No. 4. Radical 
prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 352, 19, 
pp. 1977−84. 
Boron, W.F. and Boulpaep, E.L. (2009). Medical Physiology. Second edition. 
Philadelphia PA  Saunders/Elsevier. 1337 p. 
Botrel T.E., Clark O., dos Reis R.B., Pompeo A.C., Ferreira U., Sadi M.V., Bretas F.F. 
(2014). Intermittent versus continuous androgen deprivation for locally advanced, 
recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC 
Urol. 14, 9. 
Buchanan G., Greenberg N.M., Scher H.I., Harris J.M., Marshall V.R., Tilley W.D. 
(2001). Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer 
Res. 7, 5, pp. 1273−81. 
Burkhart D.L. and Sage J. (2008). Cellular mechanisms of tumor suppression by the 
retinoblastoma gene. Nat Rev Cancer. 8, 9, pp. 671−82. 
Busund L.T., Richardsen E., Busund R., Ukkonen T., Bjørnsen T., Busch C., Stalsberg 
H. (2005). Significant expression of IGFBP2 in breast cancer compared with benign 
lesions. J Clin Pathol. 58, 4, pp. 361−6. 
Button M.R. and Staffurth J.N. (2010). Clinical Application of Image-guided 
Radiotherapy in Bladder and Prostate Cancer. Clin. Oncol. 22, 8, pp. 698−706. 
Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs 
W.B., Bova G.S., Sidransky D. (1997). Frequent inactivation of PTEN/MMAC1 in 
primary prostate cancer. Cancer Res. 57, 22, pp. 4997−5000. 
Cairns P., Evron E., Okami K., Halachmi N., Esteller, M., Herman J.G., Bose S., Wang 
S.I., Parsons R., Sidransky D. (1998). Point mutation and homozygous deletion of 
PTEN/MMAC1 in primary bladder cancers. Oncogene 16, pp. 3215−3218. 
Chauchereau A. (2011). Experimental models for the development of new medical 
treatments in prostate cancer. Eur J Cancer. 47, Suppl 3, pp. S200−14. 
Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., 
Sawyers C.L. (2004). Molecular determinants of resistance to antiandrogen therapy. Nat 
Med. 10, 1, pp. 33−9. 
Cherian M.T., Wilson E.M., Shapiro D.J. (2012). A competitive inhibitor that reduces 
recruitment of androgen receptor to androgen-responsive genes. J Biol Chem. 287, 28, 
pp. 23368−80. 
Climent J., Perez-Losada J., Quigley D.A., Kim I.J., Delrosario R., Jen K.Y., Bosch A., 
Lluch A., Mao J.H., Balmain A. (2010). Deletion of the PER3 gene on chromosome 
1p36 in recurrent ER-positive breast cancer. J Clin Oncol. 28, 23, pp. 3770−8. 
   54 
 
Coelho R.F., Rocco B., Patel M.B., Orvieto M.A., Chauhan S., Ficarra V., Melegari S., 
Palmer K.J., Patel V.R. (2010). Retropubic, laparoscopic, and robot−assisted radical 
prostatectomy: a critical review of outcomes reported by high-volume centers. J 
Endourol. 24, 12, pp. 2003−15 
Craft N., Shostak Y., Carey M., Sawyers C.L. (1999). A mechanism for 
hormone−independent prostate cancer through modulation of androgen receptor 
signaling by the HER−2/neu tyrosine kinase. Nat Med. 5, 3, pp. 280−5. 
Cross D. & Burmester J.K. (2006). Gene therapy for cancer treatment: past, present and 
future. Clin Med Res 4, pp. 218−227. 
de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones 
R.J., Goodman O.B. Jr., Saad F., Staffurth J.N., Mainwaring P., Harland S., Flaig T.W., 
Hutson T.E., Cheng T., Patterson H., Hainsworth J.D., Ryan C.J., Sternberg C.N., 
Ellard S.L., Fléchon A., Saleh M., Scholz M., Efstathiou E., Zivi A., Bianchini D., 
Loriot Y., Chieffo N., Kheoh T., Haqq C.M., Scher H.I., COU-AA-301 Investigators. 
(2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 
364, 21, pp. 1995−2005. 
de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., Gravis G., 
Bodrogi I., Mackenzie M.J, Shen L., Roessner M., Gupta S., Sartor A.O., TROPIC 
Investigators. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic 
castration-resistant prostate cancer progressing after docetaxel treatment: a randomised 
open-label trial. Lancet. 376, 9747, pp. 1147−54. 
Diamandis E.P. Prostate-specific Antigen: Its usefulness in Clinical Medicine. (1998). 
Trends Endocrinol. Metab. 9, pp. 310−316. 
Dignam J.D., Lebovitz R.M., Roeder R.G. (1983). Accurate transcription initiation by 
RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids 
Res. 11, 5, pp. 1475−89. 
Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel 
J.S., Bradley A. (1992). Mice deficient for p53 are developmentally normal but 
susceptible to spontaneous tumors. Nature. 356, 6366, pp. 215−21. 
Duan C. & Xu Q. (2005). Roles of insulin-like growth factor (IGF) binding proteins in 
regulating IGF actions. Gen. Comp. Endocrinol. 142, 1–2, pp. 44−52. 
El-Aneed, A. (2004). An overview of current delivery systems in cancer gene therapy. J. 
Control. Release 94, pp. 1– 14. 
El-Galley R.E., Keane T.E., Petros J.A., Sanders W.H., Clarke H.S., Cotsonis G.A., 
Graham S.D. Jr. (1998). Evaluation of staging lymphadenectomy in prostate cancer. 
Urology. 52, 4, pp. 663−7. 
   55 
 
Epstein J.I. (2010). An update of the Gleason grading system. J Urol. 183, 2, pp. 
433−40. 
European Cancer Observatory (ECO). [WWW]. [accessed on 25.04.2011]. Available at: 
http://eu−cancer.iarc.fr/. 
Fujita T.,  Igarashi J., Okawa E.R., Gotoh T., Manne J., Kolla V., Kim J., Zhao H., 
Pawel B.R., London W.B., Maris J.M., White P.S., Brodeur G.M. (2008) CHD5, a 
tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl. Cancer Inst. 
100, pp. 940−949. 
Fuller G.N., Rhee C.H., Hess K.R., Caskey L.S., Wang R., Bruner J.M., Yung W.K., 
Zhang W. (1999) Reactivation of insulin-like growth factor binding protein 2 
expression in glioblastoma multiforme: a revelation by parallel gene expression 
profiling. Cancer Res. 59, pp. 4228−4232. 
Gao J., Arnold J.T., Isaacs J.T. (2001) Conversion from a paracrine to an autocrine 
mechanism of androgen-stimulated growth during malignant transformation of prostatic 
epithelial cells. Cancer Res. 61, 13, pp. 5038−44. 
Gelmann E.P. (2002). Molecular biology of the androgen receptor. J Clin Oncol. 20, 13, 
pp. 3001−15. 
Gene Therapy Clinical Trials Worldwide. [WWW]. [accessed on 24.4.2011]. Available 
at: http://www.wiley.com/legacy/wileychi/genmed/clinical/. 
Gibbs M., Stanford J.L., McIndoe R.A., Jarvik G.P., Kolb S., Goode E.L, Chakrabarti 
L., Schuster E.F., Buckley V.A., Miller E.L., Brandzel S., Li S., Hood L., Ostrander 
E.A. (1999). Evidence for a rare prostate cancer-susceptibility locus at chromosome 
1p36. Am J Hum Genet. 64, 3, pp. 776−87. 
Gregory C.W, He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., Wilson E.M. 
(2001). A mechanism for androgen receptor-mediated prostate cancer recurrence after 
androgen deprivation therapy. Cancer Res. 61, 11, pp. 4315−9. 
Grossmann M.E., Huang H., Tindall D.J. (2001). Androgen receptor signaling in 
androgen-refractory prostate cancer. J Natl Cancer Inst. 93, 22, pp. 1687−97. 
Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., Chen H., Kong X., Melamed J., 
Tepper C.G., Kung H.J., Brodie A.M., Edwards J., Qiu Y. (2009). A novel androgen 
receptor splice variant is up-regulated during prostate cancer progression and promotes 
androgen depletion-resistant growth. Cancer Res. 69, 6, pp. 2305−13. 
Hanahan D. & Weinberg R. A. (2000). The hallmarks of cancer. Cell 100, 7, pp. 57−70. 
Hanahan D. & Weinberg R.A. (2011). Hallmarks of cancer: The Next Generation. Cell 
144, 4, pp. 646−674. 
   56 
 
Harrington K.J., Spitzweg C., Bateman A.R., Morris J.C., Vile R.G. (2001). Gene 
therapy for prostate cancer: current status and future prospects. The Journal of Urology 
166, pp. 1220−1233. 
Hayden A.J., Catton C., Pickles T. (2010). Radiation therapy in prostate cancer: a risk-
adapted strategy. Curr Oncol. 17 Suppl 2, pp. S18−24. 
He W.W., Sciavolino P.J., Wing J., Augustus M., Hudson P., Meissner P.S., Curtis 
R.T., Shell B.K., Bostwick D.G., Tindall D.J., Gelmann E.P., Abate-Shen C., Carter 
K.C. (1997). A novel human prostate-specific, androgen-regulated homeobox gene 
(NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 
43, 1, pp. 69−77. 
Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., Mason 
M., Matveev V., Wiegel T., Zattoni F., Mottet N. (2013). EAU Guidelines on Prostate 
Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate 
Cancer. Eur Urol. 2014 65, 2, pp. 467−79. 
Heidenreich A., Bellmunt J., Bolla M., Joniau S., Mason M., Matveev V., Mottet N., 
Schmid H.P., van der Kwast T., Wiegel T., Zattoni F., European Association of 
Urology. (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and 
treatment of clinically localised disease. Eur Urol. 59, 1, pp. 61−71. 
Helenius M., Waltering K.K., Visakorpi T. (2008). Somatic Genetic Changes in 
Prostate Cancer, Androgen Receptor Alterations. From: Current Clinical Oncology: 
Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies, Edited 
by: Pestell R.G. and Nevalainen M.T. Totowa NJ. Humana Press. pp. 99−128. 
Henrich K.O., Schwab M., Westermann F. (2012). 1p36 tumor suppression - a matter of 
dosage? Cancer Res. 72, 23, pp. 6079−88. 
Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., 
Provost N., Frohlich M.W. (2009). Integrated data from 2 randomized, double-blind, 
placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in 
advanced prostate cancer. Cancer. 115, 16, pp. 3670−9. 
Holmes K.M., Annala M., Chua C.Y., Dunlap S.M., Liu Y., Hugen N., Moore L.M., 
Cogdell D., Hu L., Nykter M., Hess K., Fuller G.N., Zhang W. (2012). Insulin-like 
growth factor-binding protein 2-driven glioma progression is prevented by blocking a 
clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl 
Acad Sci U S A. 109, 9, pp. 3475−80. 
Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand 
E.A., Murphy G.P. (1983). LNCaP model of human prostatic carcinoma. Cancer Res. 
43, 4, pp. 1809−18. 
   57 
 
Huang W., Waknitz M. (2009). ETS gene fusions and prostate cancer. Am J Transl Res. 
1, 4, pp. 341−51. 
Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang 
X.F., Yao T.P. (2002). HDAC6 is a microtubule-associated deacetylase. Nature 417, pp. 
455−458. 
Huggins C., Hodges C.V. (1941) The effect of castration, of estrogen and of androgen 
injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1, 
pp. 293−297. 
Ichimura K., Vogazianou A.P., Liu L., Pearson D.M., Bäcklund L.M., Plant K., Baird 
K., Langford C.F., Gregory S.G., Collins V.P. (2008). 1p36 is a preferential target of 
chromosome 1 deletions in astrocytic tumors and homozygously deleted in a subset of 
glioblastomas. Oncogene. 27, 14, pp. 2097−108. 
Imyanitov E.N. (2009 ). Gene polymorphisms, apoptotic capacity and cancer risk. Hum 
Genet. 125, 3, pp. 239−46. 
Ji P., Smith S.M., Wang Y., Jiang R., Song S.W., Li B., Sawaya R., Bruner J.M., Kuang 
J., Yu H., Fuller G.N., Zhang W. (2010). Inhibition of gliomagenesis and attenuation of 
mitotic transition by MIIP. Oncogene. 29, 24, pp. 3501−8. 
Joensuu H., Roberts P. J. & Teppo L. (1999). Syöpätaudit. 2. edition. Helsinki. 
Duodecim. 730 p. 
Kanety H., Madjar Y., Dagan Y., Levi J., Papa M.Z., Pariente C., Goldwasser B., 
Karasik A. (1993). Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is 
increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with 
serum prostate-specific antigen. J Clin Endocrinol Metab. 77, 1, pp. 229−33. 
Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern 
C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W., Schellhammer P.F., 
IMPACT Study Investigators. (2010). Sipuleucel-T immunotherapy for castration-
resistant prostate cancer. N Engl J Med. 363, 5, pp. 411−22 
Kitchen S.G., Shimizu S. & An D.S. (2011). Stem cell-based anti-HIV gene therapy. 
Virology 411, 2, pp. 260−272. 
Klotz L. (2012). Active surveillance for low-risk prostate cancer. F1000 Med Rep. 4, 
16. 
Klotz L. (2010). Active surveillance for prostate cancer: a review. Curr Urol Rep. 11, 3, 
pp. 165−71. 
Koga F., Tsutsumi S., Neckers L.M. (2007). Low dose geldanamycin inhibits 
hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle. 6, 
11, pp. 1393−402 
   58 
 
Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., Trapman J., 
Cleutjens K., Noordzij A., Visakorpi T., Kallioniemi O.P. (1997). Androgen receptor 
gene amplification: a possible molecular mechanism for androgen deprivation therapy 
failure in prostate cancer. Cancer Res. 57, 2, pp. 314−9. 
Kootstra N.A. & Verma I.M. (2003). Gene therapy with viral vectors. Annu Rev 
Pharmacol Toxicol 43, pp. 413−439. 
Li J., Soroka J., Buchner J. (2012). The Hsp90 chaperone machinery: conformational 
dynamics and regulation by co-chaperones. Biochim Biophys Acta. 1823, 3, pp. 
624−35. 
Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., 
Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., 
Hibshoosh H., Wigler M.H., Parsons R. (1997). PTEN, a putative protein tyrosine 
phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275, 
5308, pp. 1943−7. 
Lin B., Ferguson C., White J.T., Wang S., Vessella R., True L.D., Hood L., Nelson P.S. 
(1999). Prostate-localized and androgen-regulated expression of the membrane-bound 
serine protease TMPRSS2. Cancer Res. 59, 17, pp. 4180−4. 
Linja M.J., Savinainen K.J., Saramäki O.R., Tammela T.L., Vessella R.L., Visakorpi T. 
(2001). Amplification and overexpression of androgen receptor gene in hormone-
refractory prostate cancer. Cancer Res. 61, 9, pp. 3550−5. 
Luxton G., Hancock S.L., Boyer A.L. (2004). Dosimetry and radiobiologic model 
comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the 
prostate. Int J Radiat Oncol Biol Phys. 59, 1, pp. 267−84. 
Machtens S., Karstens J.H., Baumann R., Jonas U. (2006). Interstitial Brachytherapy 
(LDR-Brachytherapy) in the Treatment of Patients with Prostate Cancer. European 
Urology Supplements 5, 6, pp. 514−521 
MacRae E.J., Giannoudis A., Ryan R., Brown N.J., Hamdy F.C., Maitland N. & Lewis 
C.E. (2006). Gene therapy for prostate cancer: current strategies and new cell-based 
approaches. Prostate 66, 5, pp. 470−494. 
Masson-Gadais B., Houle F., Laferrière J., Huot J. (2003). Integrin αvβ3, requirement 
for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent 
phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell 
Stress Chaperones. 8, 1, pp. 37−52. 
McLeod D.G., Iversen P., See W.A., Morris T., Armstrong J., Wirth M.P., Casodex 
Early Prostate Cancer Trialists' Group. (2006). Bicalutamide 150 mg plus standard care 
vs standard care alone for early prostate cancer. BJU Int. 97, 2, pp. 247−54. 
   59 
 
Mita A.C., Denis L.J., Rowinsky E.K., Debono J.S., Goetz A.D., Ochoa L., Forouzesh 
B., Beeram M., Patnaik A., Molpus K., Semiond D., Besenval M., Tolcher A.W. 
(2009). Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel 
taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid 
tumors. Clin Cancer Res. 15, 2, pp. 723−30. 
Miyamoto H., Altuwaijri S., Chang C. (2008). Androgen Receptor in Prostate Cancer 
Progression. From: Current Clinical Oncology: Prostate Cancer: Signaling Networks, 
Genetics, and New Treatment Strategies, Edited by: Pestell R.G. and Nevalainen M.T. 
Totowa NJ. Humana Press. pp. 129−146. 
Moore M.G., Wetterau L.A., Francis M.J., Peehl D.M., Cohen P. (2003). Novel 
stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. 
Int J Cancer. 105, 1, pp. 14−9. 
Mullen J.T. & Tanabe K.K. (2002). Viral Oncolysis. Oncologist 7, pp. 106−119. 
Mullins J.K., Feng Z., Trock B.J., Epstein J.I., Walsh P.C., Loeb S. (2012). The impact 
of anatomical radical retropubic prostatectomy on cancer control: the 30-year 
anniversary. J Urol. 188, 6, pp. 2219−24. 
Paoloni-Giacobino A., Chen H., Peitsch M.C., Rossier C., Antonarakis S.E. (1997). 
Cloning of the TMPRSS2 gene, which encodes a novel serine protease with 
transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics. 44, 3, 
pp. 309−20. 
Peehl D.M. (2005). Primary cell cultures as models of prostate cancer development. 
Endocr Relat Cancer. 12, 1, pp. 19−47. 
Pelengaris S., Khan M., Evan G. (2002). c−MYC: more than just a matter of life and 
death. Nat Rev Cancer 2, pp. 764−776. 
Pienta K.J., Abate-Shen C., Agus D.B., Attar R.M., Chung L.W., Greenberg N.M., 
Hahn W.C., Isaacs J.T., Navone N.M., Peehl D.M., Simons J.W., Solit D.B., Soule 
H.R., VanDyke T.A., Weber M.J., Wu L., Vessella R.L. (2008). The current state of 
preclinical prostate cancer animal models. Prostate. 68, 6, pp. 629−39. 
Pin E., Fredolini C., Petricoin E.F. 3rd. (2013). The role of proteomics in prostate 
cancer research: biomarker discovery and validation. Clin Biochem. 46, 6, pp. 524−38. 
Pollack A., Zagars G.K., Starkschall G., Antolak J.A., Lee J.J., Huang E., von 
Eschenbach A.C., Kuban D.A., Rosen I. (2002). Prostate cancer radiation dose 
response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol 
Biol Phys. 53, 5, pp. 1097−105. 
Prostate Cancer [WWW]. Current Care Guidelines. Working Group set up by the 
Finnish Medical Society Duodecim and the Finnish Urologist Society. Helsinki: The 
   60 
 
Finnish Medical Society Duodecim 2007 [accessed on 30.1.2014]. Available at: 
http://www.kaypahoito.fi 
Prostate Health Tips. [WWW]. [accessed on 26.04.2011] Available at: 
http://www.prostatehealthtips.com/wp−content/uploads/2004/11/prostate.jpg. 
Provenge: EPAR- Public Assessment Report. EMA 3.10.2013 Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/0025
13/human_med_001680.jsp&mid=WC0b01ac058001d124 
Qian J., Hirasawa K., Bostwick D.G., Bergstralh E.J., Slezak J.M., Anderl K.L., Borell 
T.J., Lieber M.M. & Jenkins R.B. (2002). Loss of p53 and c-myc overrepresentation in 
stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. 
Mod Pathol 15, pp. 35−44. 
Renehan A.G., Jones J., Potten C.S., Shalet S.M., O'Dwyer S.T. (2000). Elevated serum 
insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal 
cancer. Br. J. Cancer 83, pp. 1344−1350. 
Roach M. 3
rd
., DeSilvio M., Valicenti R., Grignon D., Asbell S.O., Lawton C., Thomas 
C.R. Jr., Shipley W.U. (2006). Whole-pelvis, "mini-pelvis," or prostate-only external 
beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients 
treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol 
Phys. 66, 3, pp. 647−53. 
Ross M.H. and Pawlina W. (2006). Histology A Text and Atlas With correlated cell and 
molecular biology. Fifth edition. Baltimore MD. Lippincott Williams & Wilkins. 906 p. 
Rousseau S., Houle F., Kotanides H., Witte L., Waltenberger J., Landry J., Huot J. 
(2000). Vascular endothelial growth factor (VEGF)-driven actin−based motility is 
mediated by VEGFR2 and requires concerted activation of stress−activated protein 
kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion 
kinase. J Biol Chem. 275, 14, pp. 10661−72. 
Royai R., Lange P.H., Vessella R. (1996). Preclinical models of prostate cancer. Semin 
Oncol. 23, 6 Suppl 14, pp. 35−40. 
Ruizeveld de Winter J.A., Trapman J., Vermey M., Mulder E., Zegers N.D., van der 
Kwast T.H. (1991). Androgen receptor expression in human tissues: an 
immunohistochemical study. J Histochem Cytochem. 39, 7, pp. 927−36. 
Ryan C.J., Smith M.R., Fong L., Rosenberg J.E., Kantoff P., Raynaud F., Martins V., 
Lee G., Kheoh T., Kim J., Molina A., Small E.J. (2010). Phase I clinical trial of the 
CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with 
castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin 
Oncol. 28, 9, pp. 1481−8. 
   61 
 
Sack J.S., Kish K.F., Wang C., Attar R.M., Kiefer S.E., An Y., Wu G.Y., Scheffler J.E., 
Salvati M.E., Krystek S.R. Jr., Weinmann R., Einspahr H.M. (2001). Crystallographic 
structures of the ligand-binding domains of the androgen receptor and its T877A mutant 
complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A. 98, 
9, pp. 4904−9. 
Sampson N., Neuwirt H., Puhr M., Klocker H., Eder I.E. (2013). In vitro model systems 
to study androgen receptor signaling in prostate cancer. Endocr Relat Cancer. 20, 2, pp. 
R49−64. 
Saramaki O., Visakorpi T. (2007). Chromosomal aberrations in prostate cancer. Front 
Biosci. 12, pp. 3287−301. 
Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K., de Wit R., 
Mulders P., Chi K.N., Shore N.D., Armstrong A.J., Flaig T.W., Fléchon A, Mainwaring 
P., Fleming M., Hainsworth J.D., Hirmand M., Selby B., Seely L., de Bono J.S., 
AFFIRM Investigators. (2012).  Increased survival with enzalutamide in prostate cancer 
after chemotherapy. N Engl J Med. 367, 13, pp. 1187−97. 
Schütt B.S., Langkamp M., Rauschnabel U., Ranke M.B., Elmlinger M.W. (2004). 
Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J 
Mol Endocrinol. 32, 3, pp. 859−68. 
See W.A., Tyrrell C.J., CASODEX Early Prostate Cancer Trialists' Group. (2006). The 
addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival 
in men with locally advanced prostate cancer. J Cancer Res Clin Oncol. 132 Suppl 1, 
pp. S7−16. 
Seigneurin-Berny D., Verdel A., Curtet S., Lemercier C., Garin J., Rousseaux S., 
Khochbin S. (2001). Identification of components of the murine histone deacetylase 6 
complex: link between acetylation and ubiquitination signaling pathways. Mol Cell 
Biol. 21, 23, pp. 8035−44. 
Shah R.B. (2009). Current perspectives on the Gleason grading of prostate cancer. Arch 
Pathol Lab Med. 133, 11, pp. 1810−16. 
Sharma A., Yeow W.S., Ertel A., Coleman I., Clegg N., Thangavel C., Morrissey C., 
Zhang X., Comstock C.E., Witkiewicz A.K., Gomella L., Knudsen E.S., Nelson P.S., 
Knudsen K.E. (2010). The retinoblastoma tumor suppressor controls androgen signaling 
and human prostate cancer progression. J Clin Invest. 120, 12, pp. 4478−92. 
Shelley M., Harrison C., Coles B., Staffurth J., Wilt T.J., Mason M.D. (2006). 
Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev. 
CD005247. 4. 
   62 
 
Soifer H.S., Souleimanian N., Wu S., Voskresenskiy A.M., Collak F.K., Cinar B., Stein 
C.A. (2012). Direct regulation of androgen receptor activity by potent CYP17 inhibitors 
in prostate cancer cells. J Biol Chem. 287, 6, pp. 3777−87 
Song S.W., Fuller G.N., Khan A., Kong S., Shen W., Taylor E., Ramdas L., Lang F.F., 
Zhang W. (2003). IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) 
binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc Natl 
Acad Sci U S A. 100, 24, pp. 13970−5. 
Song S.W., Fuller G.N., Zheng H., Zhang W. (2005). Inactivation of the invasion 
inhibitory gene IIp45 by alternative splicing in gliomas. Cancer Res. 65, 9, pp. 3562−7. 
Sramkoski R.M., Pretlow T.G. 2
nd
., Giaconia J.M., Pretlow T.P., Schwartz S., Sy M.S., 
Marengo S.R., Rhim J.S., Zhang D., Jacobberger J.W. (1999). A new human prostate 
carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 35, 7, pp. 403−9. 
Steineck G., Helgesen F., Adolfsson J., Dickman P.W., Johansson J.E., Norlén B.J., 
Holmberg L., Scandinavian Prostatic Cancer Group Study Number 4. (2002). Quality of 
life after radical prostatectomy or watchful waiting. N Engl J Med. 347, 11, pp. 790−6. 
Taira A.V., Merrick G.S., Butler W.M., Galbreath R.W., Lief J., Adamovich E., 
Wallner K.E. (2011). Long-term outcome for clinically localized prostate cancer treated 
with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 79, 5, pp. 
1336−42. 
Tammela T.L. (2012). Endocrine prevention and treatment of prostate cancer. Mol Cell 
Endocrinol. 360, 1−2, pp. 59−67 
Tamura M., Gu J., Tran H., Yamada K.M. (1999). PTEN gene and integrin signaling in 
cancer. J Natl Cancer Inst. 91, 21, pp. 1820−8. 
Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., 
Théodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A., TAX 327 
Investigators. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for 
advanced prostate cancer. N Engl J Med. 351, 15, pp. 1502−12. 
Taplin M.E and Balk S.P. (2004). Androgen receptor: a key molecule in the progression 
of prostate cancer to hormone independence. J Cell Biochem. 91, 3, pp. 483−90. 
Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., Keer 
H.N., Balk S.P. (1995). Mutation of the androgen-receptor gene in metastatic androgen-
independent prostate cancer. N Engl J Med. 332, 21, pp. 1393−8. 
Taplin M.E. and Ho S.M. (2001). Clinical review 134: The endocrinology of prostate 
cancer. J Clin Endocrinol Metab. 86, 8, pp. 3467−77. 
Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., 
Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., 
   63 
 
Major J.E., Wilson M., Socci N.D., Lash A.E., Heguy A., Eastham J.A., Scher H.I., 
Reuter V.E., Scardino P.T., Sander C., Sawyers C.L., Gerald W.L. (2010). Integrative 
genomic profiling of human prostate cancer. Cancer Cell. 18, 1, pp. 11−22. 
The National Center for Biotechnology Information (NCBI). Database of single 
nucleotide polymorphisms [WWW]. [accessed on 10.10.2013] Available at:  
http://www.ncbi.nlm.nih.gov/snp/?term=MIIP 
Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., 
Minasian L.M., Ford L.G., Lippman S.M., Crawford E.D. (2004). Prevalence of 
prostate cancer among men with a prostate−specific antigen level < or = 4.0 ng per 
millilitre. N Engl J Med, 350, pp. 2239−2246. 
Tilley W.D., Buchanan G., Hickey T.E., Bentel J.M.. (1996). Mutations in the androgen 
receptor gene are associated with progression of human prostate cancer to androgen 
independence. Clin Cancer Res. 2, 2, pp. 277−85. 
Titus M.A., Schell M.J., Lih F.B., Tomer K.B., Mohler J.L. (2005). Testosterone and 
dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 11, 13, 
pp. 4653−7. 
Tokino T. and Nakamura Y. (2000). The role of p53-target genes in human cancer. Crit. 
Rev. Oncol./Hemato. 33, pp. 1–6. 
Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., 
Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta 
K.J., Rubin M.A., Chinnaiyan A.M. (2005). Recurrent fusion of TMPRSS2 and ETS 
transcription factor genes in prostate cancer. Science. 310, 5748, pp. 644−8. 
Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., Wongvipat J., Smith-
Jones P.M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C.D., Higano C.S., 
Beer T.M., Hung D.T., Scher H.I., Jung M.E., Sawyers C.L. (2009). Development of a 
second-generation antiandrogen for treatment of advanced prostate cancer. Science. 
324, 5928, pp. 787−90. 
Tu J.J., Rohan S., Kao J., Kitabayashi N., Mathew S., Chen Y.T. (2007). Gene fusions 
between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript 
variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol. 20, 9, 
pp. 921−8. 
Valenzuela-Fernandez A., Cabrero J.R., Serrador J.M., Sanchez-Madrid F. (2008), 
HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. 
Trends Cell Biol. 18, pp. 291−297. 
Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van 
Rooij H.C., Trapman J., Brinkmann A.O., Mulder E. (1990). A mutation in the ligand 
binding domain of the androgen receptor of human LNCaP cells affects steroid binding 
   64 
 
characteristics and response to anti-androgens. Biochem Biophys Res Commun. 173, 2, 
pp. 534−40. 
Verma I.M. and Weitzman M.D. (2005). Gene therapy: twenty-first century medicine. 
Annu Rev Biochem 74, pp. 711−738. 
Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinänen R., Palmberg C., Palotie 
A., Tammela T., Isola J., Kallioniemi O.P. (1995). In vivo amplification of the androgen 
receptor gene and progression of human prostate cancer. Nat Genet. 9, 4, pp. 401−6. 
Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A. Jr., Kinzler K.W. 
(2013). Cancer genome landscapes. Science. 339, 6127, pp. 1546−58 
Vora S.A., Wong W.W., Schild S.E., Ezzell G.A., Halyard M.Y. (2007). Analysis of 
biochemical control and prognostic factors in patients treated with either low-dose 
three-dimensional conformal radiation therapy or high-dose intensity-modulated 
radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 68, 4, pp. 
1053−8. 
Wang H., Arun B.K., Fuller G.N., Zhang W., Middleton L.P., Sahin A.A. (2008). 
IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 
breast carcinomas. Breast J. 14, pp. 261−267. 
Wang H., Shen W., Huang H., Hu L., Ramdas L., Zhou Y.H., Liao W.S., Fuller G.N., 
Zhang W. (2003). Insulin-like growth factor binding protein 2 enhances glioblastoma 
invasion by activating invasion-enhancing genes. Cancer Res. 63, 15, pp. 4315−21. 
Wang Y., Revelo M.P., Sudilovsky D., Cao M., Chen W.G., Goetz L., Xue H., Sadar 
M., Shappell S.B., Cunha G.R., Hayward S.W. (2005). Development and 
characterization of efficient xenograft models for benign and malignant human prostate 
tissue. Prostate. 64, 2, pp. 149−59. 
Wang Y., Wen J., Zhang W. (2011). MIIP, a cytoskeleton regulator that blocks cell 
migration and invasion, delays mitosis, and suppresses tumorogenesis. Curr Protein 
Pept Sci. 12, 1, pp. 68−73. 
Wang Y., Yang D., Cogdell D., Hu L., Xue F., Broaddus R., Zhang W. (2010). 
Genomic characterization of gene copy-number aberrations in endometrial carcinoma 
cell lines derived from endometrioid-type endometrial adenocarcinoma. Technol. 
Cancer Res. Treat. 9, pp. 179−189. 
Westermann S., Weber K. (2003). Post-translational modifications regulate microtubule 
function. Nat Rev Mol Cell Biol. 4, 12, pp. 938−47. 
Wong G. (2005). Introduction. From: DNA Microarray Data Analysis, Edited by 
Tuimala J. and Laine M. M. Helsinki. CSC - Scientific Computing Ltd. pp. 15−24. 
   65 
 
Wu F., Ding S., Lu J. (2013). Truncated ERG proteins affect the aggressiveness of 
prostate cancer. Med Hypotheses. 80, 4, pp. 490−3. 
Wu Y., Song S.W., Sun J., Bruner J.M., Fuller G.N., Zhang W. (2010). IIp45 inhibits 
cell migration through inhibition of HDAC6. J Biol Chem. 285, 6, pp. 3554−60. 
Yamada K.M., Araki M. (2001). Tumor suppressor PTEN: modulator of cell signaling, 
growth, migration and apoptosis. J Cell Sci. 114, Pt 13, pp. 2375−82. 
Yanada M., Yaoi T., Shimada J., Sakakura C., Nishimura M., Ito K., Terauchi K., 
Nishiyama K., Itoh K., Fushiki S. (2005). Frequent hemizygous deletion at 1p36 and 
hypermethylation downregulate RUNX3 expression in human lung cancer cell lines. 
Oncol Rep. 14, 4, pp. 817−22. 
Yu H. (2007). Cdc20: a WD40 activator for a cell cycle degradation machine. Mol Cell. 
27, 1, pp. 3−16. 
Yu Z., Chen S., Sowalsky A.G., Voznesensky O.S., Mostaghel E.A., Nelson P.S., Cai 
C., Balk S.P. (2014). Rapid induction of androgen receptor splice variants by androgen 
deprivation in prostate cancer. Clin Cancer Res. 20, 6, pp. 1590−600. 
Zhang X., Yuan Z., Zhang Y., Yong S., Salas-Burgos A., Koomen J., Olashaw N., 
Parsons J.T., Yang X.J., Dent S.R., Yao T.P., Lane W.S., Seto E. (2007), HDAC6 
modulates cell motility by altering the acetylation level of cortactin. Mol Cell. 27, 2, pp. 
197−213. 
Zhang Y., Gilquin B., Khochbin S., Matthias P. (2006). Two catalytic domains are 
required for protein deacetylation. J Biol Chem. 281, 5, pp. 2401−4. 
Zhao H., Nolley R., Chen Z., Peehl D.M. (2010). Tissue slice grafts: an in vivo model of 
human prostate androgen signaling. Am J Pathol. 177, 1, pp. 229−39. 
 
  
   66 
 
APPENDIX 1: SOLUTIONS USED IN DIGNAM’S METHOD 
Hypotonic buffer: 
10 mM Hepes, pH 7.9 
1.5mM MgCl2 
10mM KCl 
0.2mM PMSF 
0.5mM dithiothreitol (DTT) 
 
Low-salt buffer: 
20mM Hepes, pH 7.9 
25% glycerol 
1.5mM Mgcl2 
20mM KCl 
0.2mM EDTA 
0.2mM PMSF 
0.5mM DTT 
 
High-salt buffer: 
20mM Hepes, pH 7.9 
25% glycerol 
1.5mM Mgcl2 
1.2M KCl 
0.2mM EDTA 
0.2mM PMSF 
0.5mM DTT 
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APPENDIX 2: COMPOSITIONS OF GELS AND BUFFERS USED 
IN SDS-PAGE 
Separating gel: 
 
H2O     6,2 ml 
Glycerol     2 ml 
1.5 M Tris     5 ml 
30% Acrylamide-N,N’methylene-bis-acrylamide mix  6.7 ml 
10% Ammonium persulfate (APS)  100 µl 
N,N,N’,N’-tetramethylenediamine (TEMED)  10 µl 
 
Stacker gel: 
 
H2O     6.5 ml 
0.5 M Tris     2.5 ml 
30% Acrylamide-N,N’methylene-bis-acrylamide mix  1.3 ml 
10% Ammonium persulfate (APS)  90 µl 
N,N,N’,N’-tetramethylenediamine (TEMED)  10 µl 
 
Running buffer: 
 
25mM Tris 
190 mM glycine 
0.1% SDS 
 
Blotting buffer: 
 
48mM Tris 
39mM glycine 
0.0375% SDS 
10% methanol 
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APPENDIX 3: IMAGES OF PROLIFERATION ASSAYS 
 
DU145 expressing MIIP (clone A1)    DU145 empty control (clone A4) 
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APPENDIX 4: IMAGES OF MIGRATION ASSAYS 
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